In vitro activities of lipopeptides against fluconazole-resistant Candida auris
Anno: 2025
Rivista: MICROBIOLOGY SPECTRUM
Autori/autrici: Fioriti, Simona; Pallotta, Francesco; D'Achille, Gloria; Cirioni, Oscar; Simonetti, Oriana; Neubauer, Damian; Kamysz, Elzbieta; Kamysz, Wojciech; Brescini, Lucia; Caucci, Sara; Caggiano, Giuseppina; Giacometti, Andrea; Morroni, Gianluca; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/348062
Citazioni:
In vitro activities of lipopeptides against fluconazole-resistant Candida auris / Fioriti, S., Pallotta, F., D'Achille, G., Cirioni, O., Simonetti, O., Neubauer, D., Kamysz, E., Kamysz, W., Brescini, L., Caucci, S., Caggiano, G., Giacometti, A., Morroni, G., Barchiesi, F.. - In: MICROBIOLOGY SPECTRUM. - ISSN 2165-0497. - 13:4(2025). [10.1128/spectrum.01786-24]
Abstract:
Candida auris has increasingly become a global threat due to its wide range of antifungal resistances as well as its ability to sustain outbreaks in clinical settings. Two lipopeptides, C14-NleRR-NH2 (Nel) and C14-WRR-NH2 (WR), were evaluated against six fluconazole-resistant C. auris isolates. Both... molecules showed good antimicrobial activity as demonstrated by MIC determination, time-kill, and microscopy experiments. The peptides were able to inhibit fungal growth, while sub-MIC concentrations of the molecules delayed the growth. Moreover, the combinations of the two peptides with fluconazole demonstrated a reciprocal potentiation by checkerboard and time-kill experiments. Our results showed that antimicrobial peptides could be a promising option for the treatment of antifungal-resistant C. auris.
Continua a leggere

Ceftazidime–Avibactam in Critically Ill Patients: A Multicenter Observational Study
Anno: 2025
Rivista: ANTIBIOTICS
Autori/autrici: Olivieri, Silvia; Mazzanti, Sara; Gelo Signorino, Gabriele; Pallotta, Francesco; Ficola, Andrea; Canovari, Benedetta; Di Muzio, Vanessa; Di Prinzio, Michele; Cerutti, Elisabetta; Donati, Abele; Giacometti, Andrea; Barchiesi, Francesco; Brescini, Lucia
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/350612
Citazioni:
Ceftazidime–Avibactam in Critically Ill Patients: A Multicenter Observational Study / Olivieri, S., Mazzanti, S., Gelo Signorino, G., Pallotta, F., Ficola, A., Canovari, B., Di Muzio, V., Di Prinzio, M., Cerutti, E., Donati, A., Giacometti, A., Barchiesi, F., Brescini, L.. - In: ANTIBIOTICS. - ISSN 2079-6382. - 14:8(2025). [10.3390/antibiotics14080797]
Abstract:
Ceftazidime–avibactam (CAZ-AVI) is a second-generation intravenous β-lactam/β-lactamase inhibitor combination. In recent years, substantial evidence has emerged regarding the efficacy and safety of CAZ-AVI. However, data on its use in critically ill patients remain limited. Backgroun...d/Objectives: This multicenter, retrospective, observational cohort study was conducted across four Intensive Care Units (ICUs) in three hospitals in the Marche region of Italy. The primary objective was to evaluate the 30-day clinical outcomes and identify risk factors associated with 30-day clinical failure—defined as death, microbiological recurrence, or persistence within 30 days after discontinuation of therapy—in critically ill patients treated with CAZ-AVI. Methods: The study included all adult critically ill patients admitted to the participating ICUs between January 2020 and September 2023 who received CAZ-AVI for at least 72 h for the treatment of a confirmed or suspected Gram-negative bacterial (GNB) infection. Results: Among the 161 patients included in the study, CAZ-AVI treatment resulted in a positive clinical outcome (i.e., clinical improvement and 30-day survival) in 58% of cases (n = 93/161), while the overall mortality rate was 24% (n = 38/161). Relapse or persistent infection occurred in a substantial proportion of patients (25%, n = 41/161). Notably, acquired resistance to CAZ-AVI was observed in 26% of these cases, likely due to suboptimal use of the drug in relation to its pharmacokinetic/pharmacodynamic (PK/PD) properties in critically ill patients. Furthermore, treatment failure was more frequent among immunosuppressed individuals, particularly liver transplant recipients. Conclusions: This study demonstrates that the mortality rate among ICU patients treated with this novel antimicrobial combination is consistent with findings from other studies involving heterogeneous populations. However, the rapid emergence of resistance underscores the need for vigilant surveillance and the implementation of robust antimicrobial stewardship strategies.
Continua a leggere

Clinical and molecular characteristics of KPC-producing Klebsiella pneumoniae bloodstream infections: Results of a multicentre study
Anno: 2025
Rivista: JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
Autori/autrici: Brescini, Lucia; D'Achille, Gloria; Papalini, Chiara; Pallotta, Francesco; Teodori, Lucia; Pietrella, Donatella; Mencacci, Antonella; Canovari, Benedetta; Pieretti, Barbara; Mingoia, Marina; Montalti, Roberto; Morroni, Gianluca; Pasticci, Maria Bruna; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/348061
Citazioni:
Clinical and molecular characteristics of KPC-producing Klebsiella pneumoniae bloodstream infections: Results of a multicentre study / Brescini, L., D'Achille, G., Papalini, C., Pallotta, F., Teodori, L., Pietrella, D., Mencacci, A., Canovari, B., Pieretti, B., Mingoia, M., Montalti, R., Morroni, G., Pasticci, M.B., Barchiesi, F.. - In: JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE. - ISSN 2213-7173. - 41:(2025), pp. 216-223. [10.1016/j.jgar.2025.01.009]
Abstract:
Objective: Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) is a great cause of concern and often associated with bloodstream infections (BSIs) and a high mortality rate. Here we identified the risk factors of KPC-Kp BSIs observed in three Italian hospitals and studied the epidem...iology of KPC-Kp strains. Methods: A retrospective analysis of KPC-Kp BSIs was performed from 2014 to 2019 at three hospitals in central Italy (Ancona, Pesaro-Fano, and Perugia). Uni- and multi-variable analyses were performed to evaluate the clinical variables associated with mortality. Pulsed-field gel electrophoresis assay and whole-genome sequencing analysis of KPC-Kp isolates was carried out to identify antibiotic resistance genes and epidemiological relationships among the strains. Results: A total of 219 patients were considered. Mortality on day 30 was 32%, with older age, APACHE II score ≥11, Charlson Comorbidity Index ≥4, and solid tumours more frequent in patients with a negative outcome. Positive outcomes were related to combination therapy with at least two active drugs that also emerged in multivariate analysis. Most KPC-Kp strains belonged to three major sequence types (ST512, ST307, and ST101), while the most common carbapenem resistance gene variant was blaKPC-3. Conclusions: KPC-Kp BSIs remain a challenging infection with a high crude mortality rate. Patient conditions and comorbidities correlate with negative outcomes, while active drugs are correlated with better outcomes. Although collected from different hospitals, the KPC-Kp strains were epidemiologically related, suggesting inter-hospital diffusion. Timely and effective therapy, together with epidemiological surveillance, are crucial to reduce mortality and prevent the spread of nosocomial clones.
Continua a leggere

A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort
Anno: 2024
Rivista: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Autori/autrici: A Kondili, Loreta; Brancaccio, Giuseppina; Elena Tosti, Maria; Coco, Barbara; Giovanna Quaranta, Maria; Messina, Vincenzo; Ciancio, Alessia; Morisco, Filomena; Cossiga, Valentina; Claar, Ernesto; Rosato, Valerio; Ciarallo, Marianna; Cacciola, Irene; Romana Ponziani, Francesca; Cerrito, Lucia; Coppola, Roberta; Longobardi, Francesco; Biliotti, Elisa; Rianda, Alessia; Barbaro, Francesco; Coppola, Nicola; Stanzione, Maria; Barchiesi, Francesco; Fagiuoli, Stefano; Viganò, Mauro; Massari, Marco; Paolo Russo, Francesco; Ferrarese, Alberto; Laccabue, Diletta; Di Marco, Vito; Blanc, Pierluigi; Marrone, Aldo; Morsica, Giulia; Federico, Alessandro; Ieluzzi, Donatella; Rocco, Alba; Giuseppe Foschi, Francesco; Soria, Alessandro; Maida, Ivana; Chessa, Luchino; Milella, Michele; Rosselli Del Turco, Elena; Madonia, Salvatore; Chemello, Liliana; Gentile, Ivan; Toniutto, Pierluigi; Bassetti, Matteo; Surace, Lorenzo; Baiocchi, Leonardo; Pellicelli, Adriano; De Santis, Adriano; Puoti, Massimo; Degasperi, Elisabetta; Anna Niro, Grazia; Linda Zignego, Anna; Craxi, Antonio; Raimondo, Giovanni; Antonia Santantonio, Teresa; Rossana Brunetto, Maurizia; Battista Gaeta, Giovanni; Collaborating Investigators, Piter
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/347845
Citazioni:
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort / A Kondili, L., Brancaccio, G., Elena Tosti, M., Coco, B., Giovanna Quaranta, M., Messina, V., Ciancio, A., Morisco, F., Cossiga, V., Claar, E., Rosato, V., Ciarallo, M., Cacciola, I., Romana Ponziani, F., Cerrito, L., Coppola, R., Longobardi, F., Biliotti, E., Rianda, A., Barbaro, F., et al.. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1878-3511. - ELETTRONICO. - 146:(2024). [10.1016/j.ijid.2024.107115]
Abstract:
Background and aims: We aimed to characterize the epidemiologic and comorbidities profiles of patients with chronic Hepatitis D (CHD) followed in clinical practice in Italy and explored their interferon (IFN) eligibility. Methods: This was a cross-sectional study of the PITER cohort consisting of c...onsecutive HBsAg-positive patients from 59 centers over the period 2019-2023. Multivariable analysis was performed by logistic regression model. Results: Of 5492 HBsAg-positive enrolled patients, 4152 (75.6%) were screened for HDV, 422 (10.2%) were anti-HDV positive. Compared with HBsAg mono-infected, anti-HDV positive patients were more often younger, non-Italians, with a history of drug use, had elevated alanine transaminase (ALT), cirrhosis, or hepatocellular carcinoma (HCC). Compared with Italians, anti-HDV positive non-Italians were younger (42.2% age ≤ 40 years vs. 2.1%; P < 0.001), more often females (males 43.0% vs. 68.6%; P < 0.001) with less frequent cirrhosis and HCC. HDV-RNA was detected in 63.2% of anti-HDV-positive patients, who were more likely to have elevated ALT, cirrhosis, and HCC. Extrahepatic comorbidities were present in 47.4% of anti-HDV positive patients and could affect the eligibility of IFN-containing therapies in at least 53.0% of patients in care. Conclusions: CHD affects young, foreign-born patients and older Italians, of whom two-thirds had cirrhosis or HCC. Comorbidities were frequent in both Italians and non-Italians and impacted eligibility for IFN.
Continua a leggere

Genotypic and phenotypic characteristics of Candida parapsilosis bloodstream isolates: Health Care Associated Infections in a teaching Hospital in Italy
Anno: 2024
Rivista: JOURNAL OF INFECTION AND PUBLIC HEALTH
Autori/autrici: Caggiano, G.; Fioriti, S.; Morroni, G.; Apollonio, F.; Triggiano, F.; D'Achille, G.; Stefanizzi, P.; Dalfino, L.; Ronga, L.; Mosca, A.; Sparapano, E.; De Carlo, C.; Signorile, F.; Grasso, S.; Barchiesi, F.; Montagna, M. T.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/331356
Citazioni:
Genotypic and phenotypic characteristics of Candida parapsilosis bloodstream isolates: Health Care Associated Infections in a teaching Hospital in Italy / Caggiano, G., Fioriti, S., Morroni, G., Apollonio, F., Triggiano, F., D'Achille, G., Stefanizzi, P., Dalfino, L., Ronga, L., Mosca, A., Sparapano, E., De Carlo, C., Signorile, F., Grasso, S., Barchiesi, F., Montagna, M.T.. - In: JOURNAL OF INFECTION AND PUBLIC HEALTH. - ISSN 1876-0341. - ELETTRONICO. - 17:6(2024), pp. 967-974. [10.1016/j.jiph.2024.04.009]
Abstract:
Background: Candidemia is the most common healthcare associated invasive fungal infection. Over the last few decades, candidemia caused by Candida species other than Candida albicans, particularly the Candida parapsilosis complex, has emerged worldwide. The aims of this study were: to analyze the ge...notypic and phenotypic characteristics of C. parapsilosis strains isolated from blood cultures and the environment in a hospital in southern Italy, to study the possible source of infection and to correlate the isolated strains. Methods: From April to October 2022, cases of candidemia due to C. parapsilosis in patients admitted to a hospital in the Apulia region were investigated. However, 119 environmental samples from the intensive care unit were collected for identification of the likely environmental reservoir of infection. Routine antifungal (amphotericin B, anidulafungin, fluconazole) susceptibility was performed on all isolates. Whole genome sequencing was performed to study the genotypic correlation of the isolates. Biofilm biomass and metabolic activity were also quantified for all isolates. Results: A total of 43 C. parapsilosis isolates were cultured from the bloodstream of each patient in different departments, and seven surface samples were positive for C. parapsilosis. Most of the isolated yeasts (41/50; 85 %) were resistant to fluconazole and were genetically related to each other, suggesting an ongoing clonal outbreak of this pathogen. The fluconazole-susceptible isolates produced significantly more biofilm than did the resistant isolates. Metabolic activity was also higher for fluconazole-susceptible than resistant isolates. Conclusion: Cross-transmission of the microorganisms is suggested by the phenotypic similarity and genetic correlation between clinical and environmental strains observed in our study.
Continua a leggere

Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study
Anno: 2023
Rivista: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Autori/autrici: Meschiari, Marianna; Cozzi-Lepri, Alessandro; Cervo, Adriana; Granata, Guido; Rogati, Carlotta; Franceschini, Erica; Casolari, Stefania; Tatarelli, Paola; Roberto Giacobbe, Daniele; Bassetti, Matteo; Mornese Pinna, Simone; Giuseppe De Rosa, Francesco; Barchiesi, Francesco; Canovari, Benedetta; Lorusso, Carolina; Russo, Giuseppe; Cenderello, Giovanni; Cascio, Antonio; Petrosillo, Nicola; Mussini, Cristina
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/347852
Citazioni:
Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study / Meschiari, M., Cozzi-Lepri, A., Cervo, A., Granata, G., Rogati, C., Franceschini, E., Casolari, S., Tatarelli, P., Roberto Giacobbe, D., Bassetti, M., Mornese Pinna, S., Giuseppe De Rosa, F., Barchiesi, F., Canovari, B., Lorusso, C., Russo, G., Cenderello, G., Cascio, A., Petrosillo, N., Mussini, C.. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1878-3511. - ELETTRONICO. - 131:(2023), pp. 147-154. [10.1016/j.ijid.2023.04.004]
Abstract:
Objectives: Bezlotoxumab (BEZ) is a promising tool for preventing the recurrence of Clostridioides difficile infection (rCDI). The aim of the study was to emulate, in a real-world setting, the MODIFY trials in a cohort of participants with multiple risk factors for rCDI treated with BEZ in addition ...to the standard of care (SoC) versus SoC alone. Methods: A multicenter cohort study was conducted including 442 patients with Clostridioides difficile infection from 2018 to 2022, collected from 18 Italian centers. The main outcome was the 30-day occurrence of rCDI. The secondary outcomes were (i) all-cause mortality at 30 days (ii) and the composite outcome (30-day recurrence and/or all-cause death). Results: rCDI at day 30 occurred in 54 (12%): 11 in the BEZ + SoC group and 43 treated with SoC alone (8% vs 14%, odds ratio [OR] = 0.58, 95% confidence interval [CI]: 0.31-1.09, P = 0.09). The difference between BEZ + SoC versus SoC was statistically significant after controlling for confounding factors (adjusted OR = 0.40, 95% CI: 018-0.88, P = 0.02) and even more using the composite outcome (adjusted OR = 0.35, 95% CI: 0.17-0.73, P = 0.005). Conclusion: Our study confirms the efficacy of BEZ + SoC for the prevention of rCDI and death in a real-world setting. BEZ should be routinely considered among participants at high risk of rCDI regardless of age, type of Clostridioides difficile infection therapy (vancomycin vs fidaxomicin), and number of risk factors
Continua a leggere

The Clinical Characteristics of Bloodstream Infections Due to Candida spp. in Patients Hospitalized in Intensive Care Units during the SARS-CoV-2 Pandemic: The Results of a Multicenter Study
Anno: 2023
Rivista: JOURNAL OF FUNGI
Autori/autrici: Pallotta, Francesco; Brescini, Lucia; Ianovitz, Arianna; Luchetti, Ilenia; Franca, Lucia; Canovari, Benedetta; Cerutti, Elisabetta; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/329687
Citazioni:
The Clinical Characteristics of Bloodstream Infections Due to Candida spp. in Patients Hospitalized in Intensive Care Units during the SARS-CoV-2 Pandemic: The Results of a Multicenter Study / Pallotta, F., Brescini, L., Ianovitz, A., Luchetti, I., Franca, L., Canovari, B., Cerutti, E., Barchiesi, F.. - In: JOURNAL OF FUNGI. - ISSN 2309-608X. - ELETTRONICO. - 9:6(2023). [10.3390/jof9060642]
Abstract:
Candidemia is a serious health threat. Whether this infection has a greater incidence and a higher mortality rate in patients with COVID-19 is still debated. In this multicenter, retrospective, observational study, we aimed to identify the clinical characteristics associated with the 30-day mortalit...y in critically ill patients with candidemia and to define the differences in candidemic patients with and without COVID-19. Over a three-year period (2019-2021), we identified 53 critically ill patients with candidemia, 18 of whom (34%) had COVID-19 and were hospitalized in four ICUs. The most frequent comorbidities were cardiovascular (42%), neurological (17%), chronic pulmonary diseases, chronic kidney failure, and solid tumors (13% each). A significantly higher proportion of COVID-19 patients had pneumonia, ARDS, septic shock, and were undergoing an ECMO procedure. On the contrary, non-COVID-19 patients had undergone previous surgeries and had used TPN more frequently. The mortality rate in the overall population was 43%: 39% and 46% in the COVID-19 and non-COVID-19 patients, respectively. The independent risk factors associated with a higher mortality were CVVH (HR 29.08 [CI 95% 3.37-250]) and a Charlson's score of > 3 (HR 9.346 [CI 95% 1.054-82.861]). In conclusion, we demonstrated that candidemia still has a high mortality rate in patients admitted to ICUs, irrespective of infection due to SARS-CoV-2.
Continua a leggere

Candidemia in Internal Medicine: Facing the New Challenge
Anno: 2022
Rivista: MYCOPATHOLOGIA
Autori/autrici: Brescini, Lucia; Mazzanti, Sara; Morroni, Gianluca; Pallotta, Francesco; Masucci, Annamaria; Orsetti, Elena; Montalti, Roberto; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/301158
Citazioni:
Candidemia in Internal Medicine: Facing the New Challenge / Brescini, L., Mazzanti, S., Morroni, G., Pallotta, F., Masucci, A., Orsetti, E., Montalti, R., Barchiesi, F.. - In: MYCOPATHOLOGIA. - ISSN 1573-0832. - 187:2-3(2022), pp. 181-188. [10.1007/s11046-022-00624-x]
Abstract:
Candidemia is an alarming problem in critically ill patients including those admitted in Internal Medicine Wards (IMWs). Here, we analyzed all cases of candidemia in adult patients hospitalized over nine years (2010–2018) in IMWs of a 980-bedded University Hospital of Ancona, Italy. During the... study period, 218/505 (43%) episodes of candidemia occurred in IMWs patients. The cumulative incidence was 2.5/1000 hospital admission and increased significantly over time (p = 0.013). Patients were predominantly male, with a median age of 68 years. Cardiovascular diseases and solid tumors were the most frequent comorbidities. Candida albicans accounted for 51% of the cases, followed by C. parapsilosis (25%), C. tropicalis (9%) and C. glabrata (7%). Thirty-day mortality was 28% and did not increased significantly over time. By multivariate logistic regression analysis, the presence of neutropenia (OR 7.247 [CI95% 1,368–38,400; p = 0.020]), pneumonia (OR 2.323 [CI95% 1,105–4,884; p = 0.026]), and being infected with C. albicans (OR 2.642 [95% CI 1,223–5,708; p = 0.013) emerged as independent predictors of mortality. The type of antifungal therapy did not influence the outcome. Overall, these data indicate that patients admitted to IMWs are increasingly at higher risk of developing candidemia. Mortality rate remains high and significantly associated with both microbiologic- and host-related factors.
Continua a leggere

Antifungal Combinations against Candida Species: From Bench to Bedside
Anno: 2022
Rivista: JOURNAL OF FUNGI
Autori/autrici: Fioriti, Simona; Brescini, Lucia; Pallotta, Francesco; Canovari, Benedetta; Morroni, Gianluca; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/313992
Citazioni:
Antifungal Combinations against Candida Species: From Bench to Bedside / Fioriti, S., Brescini, L., Pallotta, F., Canovari, B., Morroni, G., Barchiesi, F.. - In: JOURNAL OF FUNGI. - ISSN 2309-608X. - ELETTRONICO. - 8:10(2022), p. 1077. [10.3390/jof8101077]
Abstract:
Candida spp. is the major causative agent of fungal infections in hospitalized patients and the fourth most common cause of nosocomial bloodstream infection (BSI). The availability of standardized methods for testing the in vitro activity of antifungals along with the expanding of antifungal armamen...tarium, the rising of drug-resistance and the persistence of a high mortality rate in systemic candidiasis have led to an increased interest in combination therapy. Therefore, we aimed to review the scientific literature concerning the antifungal combinations against Candida. A literature search performed in PubMed yielded 92 studies published from 2000 to 2021: 29 articles referring to in vitro studies, six articles referring to either in vitro and in vivo (i.e., animal models) studies and 57 clinical articles. Pre-clinical studies involved 735 isolates of Candida species and 12 unique types of antifungal combination approaches including azoles plus echinocandins (19%), polyenes plus echinocandins (16%), polyenes plus azoles (13%), polyenes plus 5-flucytosine ([5-FC], 13%), azoles plus 5-FC (11%) and other types of combinations (28%). Results varied greatly, often being species-, drug- and methodology-dependent. Some combinatorial regimens exerted a synergistic effect against difficult-to-treat Candida species (i.e., azoles plus echinocandins; polyenes plus 5-FC) or they were more effective than monotherapy in prevent or reducing biofilm formation and in speeding the clearance of infected tissues (i.e., polyenes plus echinocandins). In 283 patients with documented Candida infections (>90% systemic candidiasis/BSI), an antifungal combination approach could be evaluated. Combinations included: azoles plus echinocandins (36%), 5-FC-combination therapies (24%), polyenes plus azoles (18%), polyenes plus echinocandins (16%) and other types of combination therapy (6%). Case reports describing combination therapies yielded favorable response in most cases, including difficult-to-treat fungal infections (i.e., endocarditis, osteoarticular infections, CNS infections) or difficult-to-treat fungal pathogens. The only randomized trial comparing amphotericin-B deoxycholate (AMB) plus FLU vs. AMB alone for treatment of BSI in nonneutropenic patients showed that the combination trended toward improved success and more-rapid clearance from the bloodstream. In summary, antifungal combinations against Candida have produced great interest in the past two decades. To establish whether this approach can become a reliable treatment option, additional in vitro and clinical data are warranted.
Continua a leggere

In Vitro Activity of Novel Lipopeptides against Triazole-Resistant Aspergillus fumigatus
Anno: 2022
Rivista: JOURNAL OF FUNGI
Autori/autrici: Fioriti, Simona; Cirioni, Oscar; Simonetti, Oriana; Franca, Lucia; Candelaresi, Bianca; Pallotta, Francesco; Neubauer, Damian; Kamysz, Elzbieta; Kamysz, Wojciech; Canovari, Benedetta; Brescini, Lucia; Morroni, Gianluca; Barchiesi, Francesco
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/305719
Citazioni:
In Vitro Activity of Novel Lipopeptides against Triazole-Resistant Aspergillus fumigatus / Fioriti, S., Cirioni, O., Simonetti, O., Franca, L., Candelaresi, B., Pallotta, F., Neubauer, D., Kamysz, E., Kamysz, W., Canovari, B., Brescini, L., Morroni, G., Barchiesi, F.. - In: JOURNAL OF FUNGI. - ISSN 2309-608X. - (2022).

Secondary Infections in Critically Ill Patients with COVID-19: A Retrospective Study
Anno: 2022
Rivista: ANTIBIOTICS
Autori/autrici: Caiazzo, Luca; Temperoni, Chiara; Canovari, Benedetta; Simonetti, Oriana; Montalti, Roberto; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/313990
Citazioni:
Secondary Infections in Critically Ill Patients with COVID-19: A Retrospective Study / Caiazzo, L., Temperoni, C., Canovari, B., Simonetti, O., Montalti, R., Barchiesi, F.. - In: ANTIBIOTICS. - ISSN 2079-6382. - ELETTRONICO. - 11:11(2022), p. 1598. [10.3390/antibiotics11111598]
Abstract:
Patients with severe COVID-19, especially those followed in the ICU, are at risk for developing bacterial and fungal superinfections. In this study, we aimed to describe the burden of hospital-acquired superinfections in a cohort of consecutive, severe COVID-19 patients hospitalized between February... and May 2021 in the intensive care unit (ICU) department of San Salvatore Hospital in Pesaro, Italy. Among 89 patients considered, 68 (76.4%) acquired a secondary infection during their ICU stay. A total of 46 cases of ventilator-associated pneumonia (VAP), 31 bloodstream infections (BSIs) and 15 catheter-associated urinary tract infections (CAUTIs) were diagnosed. Overall mortality during ICU stay was 48%. A multivariate analysis showed that factors independently associated with mortality were male gender (OR: 4.875, CI: 1.227-19.366, p = 0.024), higher BMI (OR: 4.938, CI:1.356-17.980, p = 0.015) and the presence of VAP (OR: 6.518, CI: 2.178-19.510, p = 0.001). Gram-negative bacteria accounted for most of the isolates (68.8%), followed by Gram-positive bacteria (25.8%) and fungi (5.3%). Over half of the infections (58%) were caused by MDR opportunistic pathogens. Factors that were independently associated with an increased risk of infections caused by an MDR pathogen were higher BMI (OR: 4.378, CI: 1.467-13.064, p = 0.0008) and a higher Charlson Comorbidity Index (OR: 3.451, 95% CI: 1.113-10.700, p = 0.032). Secondary infections represent a common and life-threatening complication in critically ill patients with COVID-19. Efforts to minimize the likelihood of acquiring such infections, often caused by difficult-to-treat MDR organisms-especially in some subgroups of patients with specific risk factors-must be pursued.
Continua a leggere

Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
Anno: 2022
Rivista: ANTIBIOTICS
Autori/autrici: DI PIETRANTONIO, Maria; Brescini, Lucia; Candi, Jennifer; Morroni, Gianluca; Pallotta, Francesco; Mazzanti, Sara; Mantini, Paolo; Candelaresi, Bianca; Olivieri, Silvia; Ginevri, Francesco; Cesaretti, Giulia; Castelletti, Sefora; Cocci, Emanuele; Rosaria, G Polo; Cerutti, Elisabetta; Simonetti, Oriana; Cirioni, Oscar; Tavio, Marcello; Giacometti, Andrea; Barchiesi, Francesco
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/297812
Citazioni:
Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study / DI PIETRANTONIO, M., Brescini, L., Candi, J., Morroni, G., Pallotta, F., Mazzanti, S., Mantini, P., Candelaresi, B., Olivieri, S., Ginevri, F., Cesaretti, G., Castelletti, S., Cocci, E., Rosaria, G.P., Cerutti, E., Simonetti, O., Cirioni, O., Tavio, M., Giacometti, A., Barchiesi, F.. - In: ANTIBIOTICS. - ISSN 2079-6382. - 11:3(2022). [10.3390/antibiotics11030321]
Abstract:
Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. Methods: I...n this retrospective study, we evaluate the efficacy of ceftazidime/avibactam treatment in 81 patients with Gram-negative infection treated in our center from January 2018 to December 2019. The outcome evaluated was 30-days survival or relapse of infection after the first positive blood culture. Results: the majority of patients were 56 male (69%), with median age of 67. Charlson’s Comorbidity Index was >3 in 58 patients. In total, 46% of the patients were admitted into the medical unit, 41% in the ICU, and 14% in the surgical ward. Of the patients, 78% had nosocomial infections, and 22% had healthcare-related infections. The clinical failure rate was 35%: 13 patients died within 30 days from the onset of infection. The outcome was influenced by the clinical condition of the patients: solid organ transplantation (p = 0.003) emerged as an independent predictor of mortality; non-survival patients most frequently had pneumonia (p = 0.009) or mechanical ventilation (p = 0.049). Conclusion: Ceftazidime–avibactam showed high efficacy in infections caused by MDR Gram-negative pathogens with limited therapeutic options.
Continua a leggere

Antifungal combinations in dermatophytes
Anno: 2021
Rivista: JOURNAL OF FUNGI
Autori/autrici: Brescini, L.; Fioriti, S.; Morroni, G.; Barchiesi, F.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/294437
Citazioni:
Antifungal combinations in dermatophytes / Brescini, L., Fioriti, S., Morroni, G., Barchiesi, F.. - In: JOURNAL OF FUNGI. - ISSN 2309-608X. - 7:9(2021), p. 727. [10.3390/jof7090727]
Abstract:
Dermatophytes are the most common cause of fungal infections worldwide, affecting millions of people annually. The emergence of resistance among dermatophytes along with the availability of antifungal susceptibility procedures suitable for testing antifungal agents against this group of fungi make t...he combinatorial approach particularly interesting to be investigated. Therefore, we reviewed the scientific literature concerning the antifungal combinations against dermatophytes. A literature search on the subject performed in PubMed yielded 68 publications: 37 articles referring to in vitro studies and 31 articles referring to case reports or clinical studies. In vitro studies involved over 400 clinical isolates of dermatophytes (69% Trichophyton spp., 29% Microsporum spp., and 2% Epidermophyton floccosum). Combinations included two antifungal agents or an antifungal agent plus another chemical compound including plant extracts or essential oils, calcineurin inhibitors, peptides, disinfectant agents, and others. In general, drug combinations yielded variable results spanning from synergism to indifference. Antagonism was rarely seen. In over 700 patients with documented dermatophyte infections, an antifungal combination approach could be evaluated. The most frequent combination included a systemic antifungal agent administered orally (i.e., terbinafine, griseofulvin, or azole—mainly itraconazole) plus a topical medication (i.e., azole, terbinafine, ci-clopirox, amorolfine) for several weeks. Clinical results indicate that association of antifungal agents is effective, and it might be useful to accelerate the clinical and microbiological healing of a superficial infection. Antifungal combinations in dermatophytes have gained considerable scientific interest over the years and, in consideration of the interesting results available so far, it is desirable to continue the research in this field.
Continua a leggere

Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards
Anno: 2021
Rivista: PLOS ONE
Autori/autrici: Mazzanti, S.; Brescini, L.; Morroni, G.; Orsetti, E.; Pocognoli, A.; Donati, A.; Cerutti, E.; Munch, C.; Montalti, R.; Barchiesi, F.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/291391
Citazioni:
Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards / Mazzanti, S., Brescini, L., Morroni, G., Orsetti, E., Pocognoli, A., Donati, A., Cerutti, E., Munch, C., Montalti, R., Barchiesi, F.. - In: PLOS ONE. - ISSN 1932-6203. - ELETTRONICO. - 16:5(2021), p. e0252165. [10.1371/journal.pone.0252165]
Abstract:
Purpose Candidemia is an alarming problem in critically ill patients including those admitted in intensive care units (ICUs). We aimed to describe the clinical and microbiological characteristics of bloodstream infections (BSIs) due to Candida spp. in patients admitted to ICUs of an italian tertiary... referral university hospital over nine years. Methods A retrospective observational study of all cases of candidemia in adult patients was carried out from January 1, 2010 to December 31, 2018 at a 980-bedded University Hospital in Ancona, Italy, counting five ICUs. The incidence, demographics, clinical and microbiologic characteristics, therapeutic approaches and outcomes of ICU-patients with candidemia were collected. Non-ICU patients with candidemia hospitalized during the same time period were considered for comparison purposes. Early (7 days from the occurrence of the episode of Candida BSI) and late (30 days) mortality rates were calculated. Results During the study period, 188/505 (36%) episodes of candidemia occurred in ICU patients. Cumulative incidence was 9.9/1000 ICU admission and it showed to be stable over time. Candida albicans accounted for 52% of the cases, followed by C. parapsilosis (24%), and C. glabrata (14%). There was not a significant difference in species distribution between ICU and non-ICU patients. With the exception of isolates of C. tropicalis which showed to be fluconazole resistant in 25% of the cases, resistance to antifungals was not of concern in our patients. Early and late mortality rates, were 19% and 41% respectively, the latter being significantly higher than that observed in non-ICU patients. At multivariate analysis, factors associated with increased risk of death were septic shock, acute kidney failure, pulmonary embolism and lack of antifungal therapy. The type of antifungal therapy did not influence the outcome. Mortality did not increased significantly over time. Conclusion Neither cumulative incidence nor crude mortality of candidemia in ICU patients increased over time at our institution. However, mortality rate remained high and significantly associated with specific host-related factors in the majority of cases Copyright:
Continua a leggere

Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study
Anno: 2021
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Bartoletti, Michele; Marconi, Lorenzo; Scudeller, Luigia; Pancaldi, Livia; Tedeschi, Sara; Giannella, Maddalena; Rinaldi, Matteo; Bussini, Linda; Valentini, Ilaria; Filomena Ferravante, Anna; Potalivo, Antonella; Marchionni, Elisa; Fornaro, Giacomo; Pascale, Renato; Pasquini, Zeno; Puoti, Massimo; Merli, Marco; Barchiesi, Francesco; Volpato, Francesca; Rubin, Arianna; Saracino, Annalisa; Tonetti, Tommaso; Gaibani, Paolo; Marco Ranieri, Vito; Viale, Pierluigi; Cristini, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/300831
Citazioni:
Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study / Bartoletti, M., Marconi, L., Scudeller, L., Pancaldi, L., Tedeschi, S., Giannella, M., Rinaldi, M., Bussini, L., Valentini, I., Filomena Ferravante, A., Potalivo, A., Marchionni, E., Fornaro, G., Pascale, R., Pasquini, Z., Puoti, M., Merli, M., Barchiesi, F., Volpato, F., Rubin, A., et al.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - ELETTRONICO. - 27:1(2021), pp. 105-111. [10.1016/j.cmi.2020.09.014]
Abstract:
Objective: To assess the efficacy of corticosteroids in patients with coronavirus disease 2019 (COVID-19).Methods: A multicentre observational study was performed from 22 February through 30 June 2020. We included consecutive adult patients with severe COVID-19, defined as respiratory rate ≥30 br...eath per minute, oxygen saturation ≤93% on ambient air or arterial partial pressure of oxygen to fraction of inspired oxygen ≤300 mm Hg. We excluded patients being treated with other immunomodulant drugs, receiving low-dose corticosteroids and receiving corticosteroids 72 hours after admission. The primary endpoint was 30-day mortality from hospital admission. The main exposure variable was corticosteroid therapy at a dose of ≥0.5 mg/kg of prednisone equivalents. It was introduced as binomial covariate in a logistic regression model for the primary endpoint and inverse probability of treatment weighting using the propensity score.Results: Of 1717 patients with COVID-19 evaluated, 513 were included in the study, and of these, 170 (33%) were treated with corticosteroids. During hospitalization, 166 patients (34%) met the criteria of the primary outcome (60/170, 35% in the corticosteroid group and 106/343, 31% in the noncorticosteroid group). At multivariable analysis corticosteroid treatment was not associated with lower 30-day mortality rate (adjusted odds ratio, 0.59; 95% confidence interval (CI), 0.20-1.74; p 0.33). After inverse probability of treatment weighting, corticosteroids were not associated with lower 30-day mortality (average treatment effect, 0.05; 95% CI, -0.02 to 0.09; p 0.12). However, subgroup analysis revealed that in patients with PO2/FiO2 < 200 mm Hg at admission (135 patients, 52 (38%) treated with corticosteroids), corticosteroid treatment was associated with a lower risk of 30-day mortality (23/52, 44% vs. 45/83, 54%; adjusted odds ratio, 0.20; 95% CI, 0.04-0.90; p 0.036).Conclusions: The effect of corticosteroid treatment on mortality might be limited to critically ill COVID-19 patients.
Continua a leggere

Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches
Anno: 2021
Rivista: INFECTION AND DRUG RESISTANCE
Autori/autrici: Tortorano, Anna Maria; Prigitano, Anna; Morroni, Gianluca; Brescini, Lucia; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/294432
Citazioni:
Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches / Tortorano, A.M., Prigitano, A., Morroni, G., Brescini, L., Barchiesi, F.. - In: INFECTION AND DRUG RESISTANCE. - ISSN 1178-6973. - 14:(2021), pp. 5543-5553. [10.2147/IDR.S274872]
Abstract:
Candidemia and invasive candidiasis are the most common healthcare-associated invasive fungal infections, with a crude mortality rate of 25-50%. Candida albicans remains the most frequent etiology, followed by C. glabrata, C. parapsilosis and C. tropicalis. With the exception of a limited number of ...species (ie: C. krusei, C. glabrata and rare Candida species), resistance to fluconazole and other triazoles are quite uncommon. However, recently fluconazoleresistant C. parapsilosis, echinocandin-resistant C. glabrata and the multidrug resistant C. auris have emerged. Resistance to amphotericin B is even more rare due to the reduced fitness of resistant isolates. The mechanisms of antifungal resistance in Candida (altered drug-target interactions, reduced cellular drug concentrations, and physical barriers associated with biofilms) are analyzed. The choice of the antifungal therapy for candidemia must take into account several factors such as type of patient, presence of devices, severity of illness, recent exposure to antifungals, local epidemiology, organs involvement, and Candida species. The first-line therapy in nonneutropenic critical patient is an echinocandin switching to fluconazole in clinically stable patients with negative blood cultures and azole susceptible isolate. Similarly, an echinocandin is the drug of choice also in neutropenic patients. The treatment duration is 14 days after the first negative blood culture or longer in cases of organ involvement. An early removal of vascular catheter improves the outcome. The promising results of new antifungal molecules, such as the terpenoid derivative ibrexafungerp, the novel echinocandin with an enhanced half-life rezafungin, oteseconazole and fosmanogepix, representative of new classes of antifungals, are discussed.
Continua a leggere

Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study
Anno: 2021
Rivista: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Autori/autrici: Pasquini, Z.; Barocci, I.; Brescini, L.; Candelaresi, B.; Castelletti, S.; Iencinella, V.; Mazzanti, S.; Procaccini, G.; Orsetti, E.; Pallotta, F.; Amadio, G.; Giacometti, A.; Tavio, M.; Barchiesi, F.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/294484
Citazioni:
Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study / Pasquini, Z., Barocci, I., Brescini, L., Candelaresi, B., Castelletti, S., Iencinella, V., Mazzanti, S., Procaccini, G., Orsetti, E., Pallotta, F., Amadio, G., Giacometti, A., Tavio, M., Barchiesi, F.. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 111:(2021), pp. 31-36. [10.1016/j.ijid.2021.07.065]
Abstract:
Background: Correlation between coronavirus disease 2019 (COVID-19) and superinfections has been investigated, but remains to be fully assessed. This multi-centre study reports the impact of the pandemic on bloodstream infections (BSIs). Methods: This study included all patients with BSIs admitted t...o four Italian hospitals between 1 January and 30 June 2020. Clinical, demographic and microbiologic data were compared with data for patients hospitalized during the same period in 2019. Results: Among 26,012 patients admitted between 1 January and 30 June 2020, 1182 had COVID-19. Among the patients with COVID-19, 107 BSIs were observed, with an incidence rate of 8.19 episodes per 1000 patient-days. The incidence of BSI was significantly higher in these patients compared with patients without COVID-19 (2.72/1000 patient-days) and patients admitted in 2019 (2.76/1000 patient-days). In comparison with patients without COVID-19, BSI onset in patients with COVID-19 was delayed during the course of hospitalization (16.0 vs 5 days, respectively). Thirty-day mortality among patients with COVID-19 was 40.2%, which was significantly higher compared with patients without COVID-19 (23.7%). BSIs in patients with COVID-19 were frequently caused by multi-drug-resistant pathogens, which were often centre-dependent. Conclusions: BSIs are a common secondary infection in patients with COVID-19, characterized by increased risk during hospitalization and potentially burdened with high mortality.
Continua a leggere

High Prevalence of Antibiotic Resistance among Opportunistic Pathogens Isolated from Patients with COVID-19 under Mechanical Ventilation: Results of a Single-Center Study
Anno: 2021
Rivista: ANTIBIOTICS
Autori/autrici: Temperoni, Chiara; Caiazzo, Luca; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/300833
Citazioni:
High Prevalence of Antibiotic Resistance among Opportunistic Pathogens Isolated from Patients with COVID-19 under Mechanical Ventilation: Results of a Single-Center Study / Temperoni, C., Caiazzo, L., Barchiesi, F.. - In: ANTIBIOTICS. - ISSN 2079-6382. - ELETTRONICO. - 2021 Sep 6;10(9):1080:2021 Sep 6;10(9):1080(2021), p. 1080. [10.3390/antibiotics10091080]
Abstract:
The effect of the COVID-19 pandemic on antibiotic resistance diffusion in healthcare settings has not been fully investigated. In this study we evaluated the prevalence of antibiotic resistance among opportunistic pathogens isolated from patients with COVID-19 under mechanical ventilation. An observ...ational, retrospective, analysis was performed on confirmed cases of COVID-19 patients who were admitted to the ICU department of San Salvatore Hospital in Pesaro, Italy, from 1 February 2021 to 31 May 2021. We considered all consecutive patients aged ≥ 18, under mechanical ventilation for longer than 24 h. Eighty-nine patients, 66 (74.1%) men and 23 (25.9%) women, with a median age of 67.1 years, were recruited. Sixty-eight patients (76.4%) had at least one infection, and 11 patients (12.3%) were colonized, while in the remaining 10 patients (11.2%) neither colonization nor infection occurred. In total, 173 microorganisms were isolated. There were 73 isolates (42.2%) causing bacterial or fungal infections while the remaining 100 isolates (57.8%) were colonizers. Among Gram-negative bacteria, E. coli, A. baumannii and K. pneumoniae were the most common species. Among Gram-positive bacteria, S. aureus and E. faecalis were the most common species. Overall, there were 58/105 (55.2%) and 22/59 (37.2%) MDR isolates among Gram-negative and Gram-positive bacteria, respectively. The prevalence of an MDR microorganism was significantly higher in those patients who had been exposed to empiric antibiotic treatment before ICU admission. In conclusion, we found a high prevalence of antibiotic resistance among opportunistic pathogens isolated from patients with COVID-19 under mechanical ventilation.
Continua a leggere

Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study)
Anno: 2020
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Bartoletti, M.; Giannella, M.; Scudeller, L.; Tedeschi, S.; Rinaldi, M.; Bussini, L.; Fornaro, G.; Pascale, R.; Pancaldi, L.; Pasquini, Z.; Trapani, F.; Badia, L.; Campoli, C.; Tadolini, M.; Attard, L.; Puoti, M.; Merli, M.; Mussini, C.; Menozzi, M.; Meschiari, M.; Codeluppi, M.; Barchiesi, F.; Cristini, F.; Saracino, A.; Licci, A.; Rapuano, S.; Tonetti, T.; Gaibani, P.; Ranieri, V. M.; Viale, P.; Raumer, L.; Guerra, L.; Tumietto, F.; Cascavilla, A.; Zamparini, E.; Verucchi, G.; Coladonato, S.; Rubin, A.; Ianniruberto, S.; Francalanci, E.; Volpato, F.; Virgili, G.; Rossi, N.; Del Turco, E. R.; Guardigni, V.; Fasulo, G.; Dentale, N.; Fulgaro, C.; Legnani, G.; Campaci, E.; Basso, C.; Zuppiroli, A.; Passino, A. S.; Tesini, G.; Angelelli, L.; Badeanu, A.; Rossi, A.; Santangelo, G.; Dauti, F.; Koprivika, V.; Roncagli, N.; Tzimas, I.; Liuzzi, G. M.; Baxhaku, I.; Pasinelli, L.; Neri, M.; Zanaboni, T.; Dell'Omo, F.; Vatamanu, O.; Gori, A.; Zavatta, I.; Antonini, S.; Pironi, C.; Piccini, E.; Esposito, L.; Zuccotti, A.; Urbinati, G.; Pratelli, A.; Sarti, A.; Semprini, M.; Evangelisti, E.; D'Onofrio, M.; Sasdelli, G.; Pizzilli, G.; Pierucci, E.; Rossini, G.; Vocale, C.; Marconi, L.; Leoni, M. C.; Fronti, E.; Guaraldi, G.; Bavaro, D.; Laghetti, P.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/289956
Citazioni:
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) / Bartoletti, M., Giannella, M., Scudeller, L., Tedeschi, S., Rinaldi, M., Bussini, L., Fornaro, G., Pascale, R., Pancaldi, L., Pasquini, Z., Trapani, F., Badia, L., Campoli, C., Tadolini, M., Attard, L., Puoti, M., Merli, M., Mussini, C., Menozzi, M., Meschiari, M., et al.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - ELETTRONICO. - 26:11(2020), pp. 1545-1553. [10.1016/j.cmi.2020.08.003]
Abstract:
Objectives: We aimed to develop and validate a risk score to predict severe respiratory failure (SRF) among patients hospitalized with coronavirus disease-2019 (COVID-19). Methods: We performed a multicentre cohort study among hospitalized (>24 hours) patients diagnosed with COVID-19 from 22 ...February to 3 April 2020, at 11 Italian hospitals. Patients were divided into derivation and validation cohorts according to random sorting of hospitals. SRF was assessed from admission to hospital discharge and was defined as: SpO2 <93% with 100% FiO2, respiratory rate >30 breaths/min or respiratory distress. Multivariable logistic regression models were built to identify predictors of SRF, β-coefficients were used to develop a risk score. Trial Registration NCT04316949. Results: We analysed 1113 patients (644 derivation, 469 validation cohort). Mean (±SD) age was 65.7 (±15) years, 704 (63.3%) were male. SRF occurred in 189/644 (29%) and 187/469 (40%) patients in the derivation and validation cohorts, respectively. At multivariate analysis, risk factors for SRF in the derivation cohort assessed at hospitalization were age ≥70 years (OR 2.74; 95% CI 1.66–4.50), obesity (OR 4.62; 95% CI 2.78–7.70), body temperature ≥38°C (OR 1.73; 95% CI 1.30–2.29), respiratory rate ≥22 breaths/min (OR 3.75; 95% CI 2.01–7.01), lymphocytes ≤900 cells/mm3 (OR 2.69; 95% CI 1.60–4.51), creatinine ≥1 mg/dL (OR 2.38; 95% CI 1.59–3.56), C-reactive protein ≥10 mg/dL (OR 5.91; 95% CI 4.88–7.17) and lactate dehydrogenase ≥350 IU/L (OR 2.39; 95% CI 1.11–5.11). Assigning points to each variable, an individual risk score (PREDI-CO score) was obtained. Area under the receiver-operator curve was 0.89 (0.86–0.92). At a score of >3, sensitivity, specificity, and positive and negative predictive values were 71.6% (65%–79%), 89.1% (86%–92%), 74% (67%–80%) and 89% (85%–91%), respectively. PREDI-CO score showed similar prognostic ability in the validation cohort: area under the receiver-operator curve 0.85 (0.81–0.88). At a score of >3, sensitivity, specificity, and positive and negative predictive values were 80% (73%–85%), 76% (70%–81%), 69% (60%–74%) and 85% (80%–89%), respectively. Conclusion: PREDI-CO score can be useful to allocate resources and prioritize treatments during the COVID-19 pandemic.
Continua a leggere

Antimicrobial Resistance: A Challenge for the Future
Anno: 2020
Autori/autrici: Varaldo, Pietro Emanuele; Facinelli, Bruna; Bagnarelli, Patrizia; Menzo, Stefano; Mingoia, Marina; Brenciani, Andrea; Giacometti, Andrea; Barchiesi, Francesco; Brescini, Lucia; Cirioni, Oscar; Scalise, Giorgio; Barbadoro, Pamela; Di Stanislao, Francesco; Prospero, Emilia; D'Errico, Marcello Mario
Lingua: ENG
Classificazione IRIS: 2.1 Contributo in volume (Capitolo o Saggio)
Scheda completa IRIS: https://iris.univpm.it/handle/11566/351592
Citazioni:
Antimicrobial Resistance: A Challenge for the Future / Varaldo, P.E., Facinelli, B., Bagnarelli, P., Menzo, S., Mingoia, M., Brenciani, A., Giacometti, A., Barchiesi, F., Brescini, L., Cirioni, O., Scalise, G., Barbadoro, P., Di Stanislao, F., Prospero, E., D'Errico, M.M.. - STAMPA. - (2020), pp. 13-29. [10.1007/978-3-030-33832-9_2]
Abstract:
The global emergence of antibiotic-resistance, together with the lack of/reduced development of new antibiotic molecules, currently represents a serious public health problem as it can mean the return to a pre-antibiotic era in which infections caused by multiple-resistant pathogens are intractable.... Since the beginnings, the interest of the Institutes of Microbiology, Hygiene and Public Health, and Infectious Diseases was focused on antibiotic resistance: from molecular mechanisms, through epidemiology and clinical issues, to prevention. Future perspectives include the search of new strategies and/or new compounds for prevention and control of difficult-to-treat pathogens in a multidisciplinary approach.
Continua a leggere

Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey
Anno: 2020
Rivista: JOURNAL OF CHEMOTHERAPY
Autori/autrici: Brescini, L.; Mazzanti, S.; Orsetti, E.; Morroni, G.; Masucci, A.; Pocognoli, A.; Barchiesi, F.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/284543
Citazioni:
Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey / Brescini, L., Mazzanti, S., Orsetti, E., Morroni, G., Masucci, A., Pocognoli, A., Barchiesi, F.. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - 32:5(2020), pp. 244-250. [10.1080/1120009X.2020.1783154]
Abstract:
This study analyzed the epidemiology of bloodstream infections due to Candida spp. in a tertiary referral hospital of Ancona, Italy, and their susceptibility to antifungals. The retrospective observational study from January 2010 to December 2018 identified 504 episodes of candidemia in 461 patients.... Although Candida albicans remained the species most frequently isolated, Candida spp. other than C. albicans caused 49% of the overall episodes of candidemia. According to CLSI interpretation, most of the isolates resulted susceptible to antifungals. Azoles vs Candida tropicalis represented an exception. Echinocandin non-susceptibility was rare across the species. In conclusion, with the exception of C. tropicalis, the isolation of a non-susceptible Candida strains against azoles, echinocandins and amphotericin B was a rare event.
Continua a leggere

Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes
Anno: 2020
Rivista: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Autori/autrici: Arendrup, M. C.; Jorgensen, K. M.; Guinea, J.; Lagrou, K.; Chryssanthou, E.; Hayette, M. -P.; Barchiesi, F.; Lass-Florl, C.; Hamal, P.; Dannaoui, E.; Chowdhary, A.; Meletiadis, J.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/289959
Citazioni:
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes / Arendrup, M.C., Jorgensen, K.M., Guinea, J., Lagrou, K., Chryssanthou, E., Hayette, M.-P., Barchiesi, F., Lass-Florl, C., Hamal, P., Dannaoui, E., Chowdhary, A., Meletiadis, J.. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - ELETTRONICO. - 75:7(2020), pp. 1807-1819. [10.1093/jac/dkaa111]
Abstract:
Terbinafine resistance is increasingly reported in Trichophyton, rendering susceptibility testing particularly important in non-responding cases. We performed a multicentre evaluation of six EUCAST-based methods. Methods: Ten laboratories susceptibility tested terbinafine, itraconazole, voriconazole... and amorolfine against a blinded panel of 38 terbinafine WT and target gene mutant isolates. E.Def 9.3.1 modifications included: medium with/without addition of chloramphenicol and cycloheximide (CC), incubation at 25°C to 28°C for 5-7 days and three MIC endpoints [visually and spectrophotometrically (90%/50% inhibition)], generating 7829 MICs. Quality control (QC) strains were Aspergillus flavus ATCC 204304 and CNM-CM1813. Eyeball, ECOFFinder (where ECOFF stands for epidemiological cut-off) and derivatization WT upper limits (WT-ULs), very major errors (VMEs; mutants with MICs ≤WT-ULs) and major errors (MEs; WT isolates with MICs >WT-ULs) were determined. Results: MICs fell within the QC ranges for ATCC 204304/CNM-CM1813 for 100%/96% (voriconazole) and 84%/84% (itraconazole), respectively. Terbinafine MICs fell within 0.25-1 mg/L for 96%/92%, suggesting high reproducibility. Across the six methods, the number of terbinafine MEs varied from 2 to 4 (2.6%-5.2%) for Trichophyton rubrum and from 0 to 2 (0%-2.0%) for Trichophyton interdigitale. Modes for WT and mutant populations were at least seven 2-fold dilutions apart in all cases. Excluding one I121M/V237I T. rubrum mutant and two mixed WT/mutant T. interdigitale specimens, the numbers of VMEs were as follows: T. rubrum: CC visual, 1/67 (1.5%); CC spectrophotometric 90% inhibition, 3/59 (5.1%); and CC spectrophotometric 50% inhibition, 1/67 (1.5%); and T. interdigitale: none. Voriconazole and amorolfine MICs were quite uniform, but trailing growth complicated determination of itraconazole visual and spectrophotometric 90% inhibition MIC. Conclusions: Although none of the laboratories was experienced in dermatophyte testing, error rates were low. We recommend the CC spectrophotometric 50% inhibition method and provide QC ranges and WT-ULs for WT/non-WT classification.
Continua a leggere

A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication
Anno: 2020
Rivista: JOURNAL OF TRANSLATIONAL MEDICINE
Autori/autrici: Orlandi, Chiara; Canovari, Benedetta; Bozzano, Federica; Marras, Francesco; Pasquini, Zeno; Barchiesi, Francesco; De Maria, Andrea; Magnani, Mauro; Casabianca, Anna
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/289958
Citazioni:
A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication / Orlandi, C., Canovari, B., Bozzano, F., Marras, F., Pasquini, Z., Barchiesi, F., De Maria, A., Magnani, M., Casabianca, A.. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - ELETTRONICO. - 18:1(2020). [10.6084/m9.figshare.12332231.v1]
Abstract:
Background: The persistence of HIV-1 in reservoir cells is one of the major obstacles to eradicating the virus in infected individuals receiving combination antiretroviral therapy (ART). HIV-1 persists in infected cells as a stable integrated genome and more labile unintegrated DNA (uDNA), which inc...ludes linear, 1-LTR and 2-LTR circular DNA. 2-LTR circle DNA, although less abundant, is considered a surrogate marker of recent infection events and is currently used instead of the other unintegrated species as a diagnostic tool. This pilot study aimed to investigate how to best achieve the measurement of uDNA. Methods: A comparative analysis of two qPCR-based methods (U-assay and 2-LTR assay) was performed on the blood of 12 ART-naïve, 14 viremic and 29 aviremic On-ART patients and 20 untreated spontaneous controllers (HIC), sampled at a single time point. Results: The U-assay, which quantified all unintegrated DNA species, showed greater sensitivity than the 2-LTR assay (up to 75%, p < 0.0001), especially in viremic subjects, in whom other forms, in addition to 2-LTR circles, may also accumulate due to active viral replication. Indeed, in aviremic On-ART samples, the U-assay unexpectedly measured uDNA in a higher proportion of samples (76%, 22/29) than the 2-LTR assay (41%, 12/29), (p = 0.0164). A trend towards lower uDNA levels was observed in aviremic vs viremic On-ART patients, reaching significance when we combined aviremic On-ART and HIC (controllers) vs Off-ART and viremic On-ART subjects (non-controllers) (p = 0.0003), whereas 2-LTR circle levels remained constant (p ≥ 0.2174). These data were supported by the high correlation found between uDNA and total DNA (r = 0.69, p < 0.001). Conclusions: The great advantage of the U-assay is that, unlike the 2-LTR assay, it allows the accurate evaluation of the totality of uDNA that can still be measured even during successful ART when plasma viremia is below the cut-off of common clinical tests (< 50 copies/mL) and 2-LTR circles are more likely to be under the quantification limit. UDNA measurement in blood cells may be used as a biomarker to reveal a so far hidden or underestimated viral reservoir. The potential clinical relevance of uDNA quantification may lead to improvements in diagnostic methods to support clinical strategies.
Continua a leggere

An (Italian) proposal for a comprehensive approach to infections across the surgical pathway
Anno: 2020
Rivista: WORLD JOURNAL OF EMERGENCY SURGERY
Autori/autrici: Sartelli, Massimo; Pagani, Leonardo; Iannazzo, Stefania; Luisa Moro, Maria; Viale, Pierluigi; Pan, Angelo; Ansaloni, Luca; Coccolini, Federico; D'Errico, Marcello M.; Agreiter, Iris; Amadio Nespola, Giorgio; Barchiesi, Francesco; Benigni, Valeria; Binazzi, Raffaella; Cappanera, Stefano; Chiodera, Alessandro; Cola, Valentina; Corsi, Daniela; Cortese, Francesco; Crapis, Massimo; Cristini, Francesco; D’Arpino, Alessandro; De Simone, Belinda; Di Bella, Stefano; Di Marzo, Francesco; Donati, Abele; Elisei, Daniele; Fantoni, Massimo; Ferrari, Anna; Foghetti, Domitilla; Francisci, Daniela; Gattuso, Gianni; Giacometti, Andrea; Cesare Gesuelli, Guido; Marmorale, Cristina; Martini, Enrica; Meledandri, Marcello; Murri, Rita; Padrini, Daniela; Palmieri, Dalia; Pauri, Paola; Rebagliati, Carla; Ricchizzi, Enrico; Sambri, Vittorio; Maria Schimizzi, Anna; Siquini, Walter; Scoccia, Loredana; Scoppettuolo, Giancarlo; Sganga, Gabriele; Storti, Nadia; Tavio, Marcello; Toccafondi, Giulio; Tumietto, Fabio; Viaggi, Bruno; Vivarelli, Marco; Tranà, Cristian; Raso, Melina; Maria Labricciosa, Francesco; Dhingra and Fausto Catena, Sameer
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/274969
Citazioni:
An (Italian) proposal for a comprehensive approach to infections across the surgical pathway / Sartelli, M., Pagani, L., Iannazzo, S., Luisa Moro, M., Viale, P., Pan, A., Ansaloni, L., Coccolini, F., D'Errico, M.M., Agreiter, I., Amadio Nespola, G., Barchiesi, F., Benigni, V., Binazzi, R., Cappanera, S., Chiodera, A., Cola, V., Corsi, D., Cortese, F., Crapis, M., et al.. - In: WORLD JOURNAL OF EMERGENCY SURGERY. - ISSN 1749-7922. - ELETTRONICO. - 15:1(2020), pp. 13.1-13.26. [10.1186/s13017-020-00295-3]
Abstract:
Despite evidence supporting the effectiveness of best practices in infection prevention and management, many healthcare workers fail to implement them and evidence-based practices tend to be underused in routine practice. Prevention and management of infections across the surgical pathway should a...lways focus on collaboration among all healthcare workers sharing knowledge of best practices. To clarify key issues in the prevention and management of infections across the surgical pathway, a multidisciplinary task force of experts convened in Ancona, Italy, on May 31, 2019, for a national meeting. This document represents the executive summary of the final statements approved by the expert panel.
Continua a leggere

Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU
Anno: 2020
Rivista: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Autori/autrici: Pasquini, Z.; Montalti, R.; Temperoni, C.; Canovari, B.; Mancini, M.; Tempesta, M.; Pimpini, D.; Zallocco, N.; Barchiesi, F.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/289957
Citazioni:
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU / Pasquini, Z., Montalti, R., Temperoni, C., Canovari, B., Mancini, M., Tempesta, M., Pimpini, D., Zallocco, N., Barchiesi, F.. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - ELETTRONICO. - 75:11(2020), pp. 3359-3365. [10.1093/jac/dkaa321]
Abstract:
Background: Remdesivir is a prodrug with in vitro activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Its clinical efficacy in patients with COVID-19 under mechanical ventilation remains to be evaluated. Methods: This study includes patients under mechanical ventilation wi...th confirmed SARS-CoV-2 infection admitted to the ICU of Pesaro hospital between 29 February and 20 March 2020. During this period, remdesivir was provided on a compassionate use basis. Clinical characteristics and outcome of patients treated with remdesivir were collected retrospectively and compared with those of patients hospitalized in the same time period. Results: A total of 51 patients were considered, of which 25 were treated with remdesivir. The median (IQR) age was 67 (59–75.5) years, 92% were men and symptom onset was 10 (8–12) days before admission to ICU. At baseline, there was no significant difference in demographic characteristics, comorbidities and laboratory values between patients treated and not treated with remdesivir. Median follow-up was 52 (46–57) days. Kaplan–Meier curves showed significantly lower mortality among patients who had been treated with remdesivir (56% versus 92%, P &lt; 0.001). Cox regression analysis showed that the Charlson Comorbidity Index was the only factor that had a significant association with higher mortality (OR 1.184; 95% CI 1.027–1.365; P = 0.020), while the use of remdesivir was associated with better survival (OR 3.506; 95% CI 1.768–6.954; P &lt; 0.001). Conclusions: In this study the mortality rate of patients with COVID-19 under mechanical ventilation is confirmed to be high. The use of remdesivir was associated with a significant beneficial effect on survival.
Continua a leggere

Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors
Anno: 2019
Rivista: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
Autori/autrici: Orsetti, Elena; Brescini, Lucia; Mazzanti, Sara; Trave, Francesca; Morroni, Gianluca; Pocognoli, Antonella; Berardi, Rossana; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/266489
Citazioni:
Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors / Orsetti, E., Brescini, L., Mazzanti, S., Trave, F., Morroni, G., Pocognoli, A., Berardi, R., Barchiesi, F.. - In: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. - ISSN 0934-9723. - STAMPA. - 38:8(2019), pp. 1499-1505. [10.1007/s10096-019-03578-z]
Abstract:
Systemic infections due to Candida spp. is common among immunocompromised patients, including those with solid tumors (ST). Clinical characteristics of candidemia in 114 patients with ST were compared with those of 249 candidemic patients without ST (non-ST). Patients with ST were more likely to be ...hospitalized in medical departments, to have a significantly higher Charlson's score and to undergo a significantly later central venous catheter (CVC) removal (P < 0.001). Similarly, the use of total parenteral nutrition was more common in ST patients (P = 0.026). Although there was a trend toward a more appropriate use of antifungal therapy in ST (60%) than in non-ST patients (49%), the difference was not statistically significant (P = 0.059). Thirty-day mortality was significantly higher in ST (49%) than in non-ST patients (36%, P = 0.016). Multivariate analysis showed that either higher age or septic shock was an independent risk factor for mortality in both groups of patients. Conversely, a CVC-unrelated candidemia represented an independent risk factor for mortality in ST patients (HR 3.581 [CI 95% 1.412-9.087, P = 0.007]). Overall, these data show that candidemia in ST patients is characterized by an extremely high mortality rate.
Continua a leggere

Prevalence and predictors of malignancies in HIV patients: results of a retrospective multicentric Italian cohort.
Anno: 2019
Rivista: Le Infezioni in Medicina
Autori/autrici: Mazzotta, E; Riccardi, N; Tontodonati, M; Gabrielli, C; Mazzocato, S; Mazzetti, M; Falasca, K; Vecchiet, J; Barchiesi, F; Francisci, D; Siri, G; Cenderello, G; Parruti, G.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/276027
Citazioni:
Prevalence and predictors of malignancies in HIV patients: results of a retrospective multicentric Italian cohort / Mazzotta, E., Riccardi, N., Tontodonati, M., Gabrielli, C., Mazzocato, S., Mazzetti, M., Falasca, K., Vecchiet, J., Barchiesi, F., Francisci, D., Siri, G., Cenderello, G., Parruti, G.. - ELETTRONICO. - 27:(2019), pp. 53-57.
Abstract:
We report the sharp reduction in the incidence of AIDS defining cancers in a multicentric, retrospective study carried out since 1991 and involving six Infectious Diseases Units spread across Italy. However, due to the parallel increase in non-AIDS defining cancers, cancer incidence was not reduced.... Focusing on predictors of death in HIV-positive patients with neoplastic disease, multivariate models revealed that males as well as drug abusers were independently associated with a poor clinical outcome.
Continua a leggere

Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy
Anno: 2019
Rivista: BMC INFECTIOUS DISEASES
Autori/autrici: Brescini, L.; Morroni, G.; Valeriani, C.; Castelletti, S.; Mingoia, M.; Simoni, S.; Masucci, A.; Montalti, R.; Vivarelli, M.; Giacometti, A.; Barchiesi, F.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/271555
Citazioni:
Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy / Brescini, L., Morroni, G., Valeriani, C., Castelletti, S., Mingoia, M., Simoni, S., Masucci, A., Montalti, R., Vivarelli, M., Giacometti, A., Barchiesi, F.. - In: BMC INFECTIOUS DISEASES. - ISSN 1471-2334. - 19:1(2019), p. 611. [10.1186/s12879-019-4268-9]
Abstract:
BACKGROUND: Bloodstream infections (BSI) due to Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) have become an important problem and they are associated with a high mortality rate. The aim of our study was to evaluate the clinical and epidemiological characteristics of KP...C-Kp from BSIs. METHODS: In this retrospective cohort study, conducted in a tertiary referral center in Italy, 112 patients with KPC-Kp BSIs diagnosed between February 2011 and December 2015 were identified. We evaluated the mortality at 30 days from the first positive blood culture. Survivor and non-survivor subgroups were compared to identify predictors of mortality. RESULTS: The overall crude mortality was 35%. APACHE II score ≥ 15, septic shock at BSI onset, immunosuppressive therapy during the 30 days before the BSI onset, and the lack of a combination therapy with at least 2 active drugs emerged as independent predictors of mortality. Excluding patients with inadequate therapy, the mortality decreased to 25% while an APACHE II score ≥ 15 and the presence of septic shock remained independently associated with a negative outcome. Two different pulsotypes were identified: pulsotype A belonged to ST512 and carried KPC-3 and pulsotype B belonged to ST307 and carried KPC-2. CONCLUSIONS: This study confirmed a high mortality rate of KPC-Kp BSIs. The outcome is heavily influenced by the patient's clinical conditions. A therapeutic approach including a combination with at least two active drugs in vitro can improve the prognosis, unless patients received an appropriate therapy.
Continua a leggere

Characterisation of candidemia in patients with recent surgery: A 7-year experience
Anno: 2019
Rivista: MYCOSES
Autori/autrici: Orsetti, E; Brescini, L; Mazzanti, S; Trave, F; Morroni, G; Masucci, A; Barchiesi, F.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/276022
Citazioni:
Characterisation of candidemia in patients with recent surgery: A 7-year experience / Orsetti, E., Brescini, L., Mazzanti, S., Trave, F., Morroni, G., Masucci, A., Barchiesi, F.. - In: MYCOSES. - ISSN 0933-7407. - STAMPA. - 62:11(2019), pp. 1056-1063. [10.1111/myc.12988.]
Abstract:
Candidemia can complicate major surgical procedures. However, literature data are scanty on this topic. In this study, we evaluated the epidemiology, clinical and microbiologic characteristics and outcome of candidemia in adult patients with recent surgery hospitalised in a single University Hospita...l in Central Italy from 2010 to 2016. Of the 304 episodes of candidemia, 160 (53%) occurred in surgical patients (SPs) while the remaining 144 (47%) in patients without history of recent surgery (non-SPs). Although either underlying chronic comorbidities (ie haematological malignancies, neurological and gastrointestinal diseases) or acute complications (ie pneumonia and septic shock) were less likely to occur in SPs than in non-SPs, 30-day mortality did not differ between groups being 38% and 42%, respectively. The specific risk factors significantly more common in SPs who died within 30 days were as follows: male gender, older age, being hospitalised in ICU rather than in other wards, having a higher Charlson's score, undergoing previous invasive procedures, haemodialysis, the presence of pneumonia, septic shock, acute kidney failure and the type of surgery. In particular, either gastrointestinal or cardiovascular surgeries were characterised by the highest mortality rates. Multivariate analysis showed that the occurrence of septic shock (HR 10.3131 [CI95% 1.176-90.466; P = .035] and ICU stay (HR 2.016 [CI95% 1.178-3.448; P = .011] was independently associated with higher mortality in SPs. Overall, these data show that candidemia in SPs is characterised by significant mortality and distinctive features.
Continua a leggere

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial
Anno: 2018
Rivista: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Autori/autrici: Fabbiani, Massimiliano; Gagliardini, Roberta; Ciccarelli, Nicoletta; Roldan, Eugenia Quiros; Latini, Alessandra; D'Ettorre, Gabriella; Antinori, Andrea; Castagna, Antonella; Orofino, Giancarlo; Francisci, Daniela; Chinello, Pierangelo; Madeddu, Giordano; Grima, Pierfrancesco; Rusconi, Stefano; Del Pin, Barbara; Lombardi, FRANCESCA ELENA; D'Avino, Alessandro; Focà, Emanuele; Colafigli, Manuela; Cauda, Roberto; Di Giambenedetto, Simona; De Luca, Andrea; Mondi, A.; Borghetti, A.; Baldonero, E.; Belmonti, S.; Lamonica, S.; Sidella, L.; Tamburrini, E.; Visconti, E.; Giacometti, A.; Barchiesi, F.; Castelli, P.; Cirioni, O.; Mazzocato, S.; DI PIETRO, Marinella; Blanc, P.; Degli Esposti, A.; Mariabelli, E.; Marini, Stefano; Poggi, A.; Quiros Roldan, E.; Amadasi, S.; Apostoli, A.; Biasi, L.; Bonito, A.; Brianese, N.; Compostella, S.; Ferraresi, A.; Motta, D.; Mughini, M. T.; Celesia, B. M.; Gussio, M.; Sofia, S.; Tana, M.; Tundo, P.; Viscoli, C.; De Hoffer, L.; Di Biagio, A.; Grignolo, S.; Parisini, A.; Schenone, E.; Taramasso, L.; Manconi, P. E.; Boccone, A.; Ortu, F.; Piano, P.; Serusi, L.; Puoti, M.; Moioli, M. C.; Rossotti, R.; Travi, G.; Ventura, Fiammetta; Galli, M.; Di Nardo Stuppino, S.; Di Cristo, V.; Giacomelli, Andrea; Vimercati, V.; Viale, P.; Gori, A.; Rizzardini, G.; Capetti, A.; Carenzi, L.; Mazza, F.; Meraviglia, P.; DE ROSA, Stefano; Zucchi, Paolo; Mineo, Martina; Giuliani, M.; Pacifici, A.; Pimpinelli, F.; Solivetti, F.; Stivali, F.; Angelici, Francesca; Bellagamba, Roberta; Delle Rose, D.; Fezza, R.; Libertone, R.; Mosti, S.; Narciso, P.; Nicastri, E.; Ottou, S.; Tomassi, C.; Vlassi, C.; Zaccarelli, M.; Zoppè, F.; Vullo, V.; Altavilla, F.; Ceccarelli, Gabriele; Fantauzzi, A.; Gebremeskel, S.; Lo Menzo, S.; Mezzaroma, I.; Tierno, F.; Petrosillo, N.; Boumis, E.; Cicalini, S.; Grilli, E.; Musso, M.; Stella, C.; Mura, M. S.; Bagella, P.; Mannazzu, M.; Soddu, V.; Caramello, P.; Carcieri, C.; Carosella, S.; Farenga, M.; Scotton, P. G.; Rossi, M. C.; Concia, E.; Corsini, F.; Gricolo, C.; Lanzafame, M.; Lattuada, E.; Leonardi, S.; Rigo, F.; Lazzarin, A.; Bigoloni, A.; Carini, E.; Nozza, S.; Spagnuolo, V.; Belfiori, B.; Malincarne, L.; Schiaroli, E.; Sfara, C.; Tosti, A.; Sacchini, D.; Ruggieri, A.; Valdatta, C.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/264136
Citazioni:
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial / Fabbiani, M., Gagliardini, R., Ciccarelli, N., Roldan, E.Q., Latini, A., D'Ettorre, G., Antinori, A., Castagna, A., Orofino, G., Francisci, D., Chinello, P., Madeddu, G., Grima, P., Rusconi, S., Del Pin, B., Lombardi, F.E., D'Avino, A., Focà, E., Colafigli, M., Cauda, R., et al.. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - STAMPA. - 73:7(2018), pp. 1955-1964. [10.1093/jac/dky123]
Abstract:
Objectives: To investigate the long-term safety and efficacy of a treatment switch to dual ART with atazanavir/ritonavir + lamivudine versus continuing a standard regimen with atazanavir/ritonavir + 2NRTI in virologically suppressed patients. Methods: ATLAS-M is a ...96 week open-label, randomized, non-inferiority (margin -12%) trial enrolling HIV-infected adults on atazanavir/ritonavir + 2NRTI, with stable HIV-RNA <50 copies/mL and CD4 counts >200 cells/mm3. At baseline, patients were randomized 1:1 to switch to atazanavir/ritonavir + lamivudine or to continue the previous regimen. Here, we report the 96 week efficacy and safety data. The study was registered with ClinicalTrials.gov, number NCT01599364. Results: Overall, 266 subjects were enrolled (133 in each arm). At 96 weeks, in the ITT population, patients free of treatment failure totalled 103 (77.4%) with atazanavir/ritonavir + lamivudine and 87 (65.4%) with triple therapy (difference +12.0%, 95% CI +1.2/+22.8, P = 0.030), demonstrating the superiority of dual therapy. Two (1.5%) and 9 (6.8%) virological failures occurred in the dual-therapy arm and the triple-therapy arm, respectively, without development of resistance to any study drug. Clinical adverse events occurred at similar rates in both arms. A higher frequency of grade 3-4 hyperbilirubinemia (66.9% versus 50.4%, P = 0.006) and hypertriglyceridaemia (6.8% versus 1.5%, P = 0.031) occurred with dual therapy, although this never led to treatment discontinuation. A significant improvement in renal function and lumbar spine bone mineral density occurred in the dual-therapy arm. The evolution of CD4, HIV-DNA levels and neurocognitive performance was similar in both arms. Conclusions: In this randomized study, a treatment switch to atazanavir/ritonavir + lamivudine was superior over the continuation of atazanavir/ritonavir + 2NRTI in virologically suppressed patients, with a sustained benefit in terms of improved renal function and bone mineral density.
Continua a leggere

How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates
Anno: 2018
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Guinea, J.; Verweij, P. E.; Meletiadis, J.; Mouton, J. W.; Barchiesi, F.; Arendrup, M. C.; Arikan-Akdagli, S.; Castanheira, M.; Chryssanthou, E.; Friberg, N.; Järv, H.; Klimko, N.; Kurzai, O.; Lagrou, K.; Lass-Flörl, C.; Mares, M.; Matos, T.; Moore, C. B.; Muehlethaler, K.; Rogers, T. R.; Andersen, C. T.; Velegraki, A.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/264135
Citazioni:
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates / Guinea, J., Verweij, P.E., Meletiadis, J., Mouton, J.W., Barchiesi, F., Arendrup, M.C., Arikan-Akdagli, S., Castanheira, M., Chryssanthou, E., Friberg, N., Järv, H., Klimko, N., Kurzai, O., Lagrou, K., Lass-Flörl, C., Mares, M., Matos, T., Moore, C.B., Muehlethaler, K., Rogers, T.R., et al.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - ELETTRONICO. - (2018). [10.1016/j.cmi.2018.09.008]
Abstract:
ACKGROUND: The emergence of azole-resistant Aspergillus fumigatus isolates is a matter of significant concern in Europe, with countries reporting resistance rates (which can be as high as 30%) in hospitalized patients. Consequently, the treatment guidelines in The Netherlands, the country with th...e highest documented prevalence of azole-resistant A. fumigatus, has just been revised to now recommend initial therapy with combination therapy until the susceptibility pattern is known. Therefore, susceptibility testing of clinically relevant isolates has been strongly recommended in the ESCMID-EFISG aspergillosis guidelines. Furthermore, mixed azole-susceptible and azole-resistant (isogenic as well as non-isogenic) infections have been reported to occur, which implies that colonies of clinical cultures may harbour various phenotypes of azole susceptibility. OBJECTIVES: The EUCAST-AFST (European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing) has released a new screening method document (E.Def 10.1) for the detection of azole-resistant A. fumigatus isolates and updated the QC tables for antifungal susceptibility testing with associated QC endpoints. This review described in detail how to perform the screening test. SOURCES: This "How to document" is based on the EUCAST azole agar screening method document E.Def 10.1 and the QC tables for antifungal susceptibility testing document, v 2.0 (available at http://www.eucast.org/ast_of_fungi/qcafsttables/) CONTENTS: The method is based on the inoculation of azole-containing and azole-free agars and visual determination of fungal growth after one and two days of incubation. It can easily be implemented in routine laboratories of clinical microbiology and has been validated for simultaneous testing of up to five A. fumigatus colonies using itraconazole and voriconazole (mandatory), and posaconazole (optional). IMPLICATIONS: This easy-to-use screening procedure for the detection of azole resistance in clinical A. fumigatus isolates will allow rapid testing in the daily routine of the microbiology laboratory and thus facilitate earlier appropriate therapy.
Continua a leggere

Estimated burden of fungal infections in Italy
Anno: 2018
Rivista: JOURNAL OF INFECTION
Autori/autrici: Bassetti, Matteo; Carnelutti, Alessia; Peghin, Maddalena; Aversa, Franco; Barchiesi, Francesco; Girmenia, Corrado; Pagano, Livio; Sanguinetti, Maurizio; Tortorano, Anna Maria; Montagna, Maria Teresa; Viale, Pierluigi; Viscoli, Claudio; Denning, David W.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/264137
Citazioni:
Estimated burden of fungal infections in Italy / Bassetti, M., Carnelutti, A., Peghin, M., Aversa, F., Barchiesi, F., Girmenia, C., Pagano, L., Sanguinetti, M., Tortorano, A.M., Montagna, M.T., Viale, P., Viscoli, C., Denning, D.W.. - In: JOURNAL OF INFECTION. - ISSN 0163-4453. - 76:1(2018), pp. 103-106. [10.1016/j.jinf.2017.07.008]

Acute histoplasmosis in immunocompetent travelers: a systematic review of literature
Anno: 2018
Rivista: BMC INFECTIOUS DISEASES
Autori/autrici: Staffolani, S; Buonfrate, D; Angheben, A; Gobbi, F; Giorli, G; Guerriero, M; Bisoffi, Z; Barchiesi, F
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/264132
Citazioni:
Acute histoplasmosis in immunocompetent travelers: a systematic review of literature / Staffolani, S., Buonfrate, D., Angheben, A., Gobbi, F., Giorli, G., Guerriero, M., Bisoffi, Z., Barchiesi, F.. - In: BMC INFECTIOUS DISEASES. - ISSN 1471-2334. - ELETTRONICO. - XVIII:(2018), p. 673. [10.1186/s12879-018-3476-z]
Abstract:
BACKGROUND: Histoplasmosis is a fungal infection highly endemic in the American continent. The disease can be severe in immunocompromised subjects. In immunocompetent subjects the clinical manifestations are variable. Aim of this work was to review the cases of acute histoplasmosis in immunocompe...tent travelers reported in literature. METHODS: A systematic review of literature was conducted. Electronic search was performed in Pubmed and LILACS. Two reviewers independently extracted data on demographic, clinical and radiological features, and treatment. Cases were classified according to Wheat's definitions. RESULTS: Seventy-one studies were included in the analysis, comprising a total of 814 patients. Twenty-one patients diagnosed at the Centre of Tropical Diseases, Negrar (VR), Italy were also included. The most common travel destination was Central America (168 people, 29.8%); the most common way of exposure to histoplasma was the exploration of caves and/or contact with bat guano (349 people, 60.9%). The multivariate logistic regression model showed association between the development of disseminated histoplasmosis (DH) and activities that involved the exploration of caves and/or the contact with bats' guano (adjusted OR: 34.20 95% CI: 5.29 to 220.93) or other outdoor activities (adjusted OR: 4.61 95% CI: 1.09 to 19.56). No significant difference in the attack rate between countries of destination was observed (p-value: 0.8906, Kruskal-Wallis test). CONCLUSIONS: Histoplasmosis often causes no or mild symptoms in immunocompetent individuals, although a severe syndrome may occur. The infection can mimic other diseases, and the epidemiological risk of exposure is an important clue to raise the index of suspicion.
Continua a leggere

High rate of ceftobiprole resistance among clinical methicillin-resistant Staphylococcus aureus isolates from a hospital in central Italy
Anno: 2018
Rivista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Autori/autrici: Morroni, Gianluca; Brenciani, Andrea; Brescini, Lucia; Fioriti, Simona; Simoni, Serena; Pocognoli, Antonella; Mingoia, Marina; Giovanetti, Eleonora; Barchiesi, Francesco; Giacometti, Andrea; Cirioni, Oscar
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/264133
Citazioni:
High rate of ceftobiprole resistance among clinical methicillin-resistant Staphylococcus aureus isolates from a hospital in central Italy / Morroni, G., Brenciani, A., Brescini, L., Fioriti, S., Simoni, S., Pocognoli, A., Mingoia, M., Giovanetti, E., Barchiesi, F., Giacometti, A., Cirioni, O.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 62:12(2018). [10.1128/AAC.01663-18]
Abstract:
Ceftobiprole is a fifth-generation cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). One-year surveillance at the Regional Hospital of Ancona (Italy) disclosed a 12% ceftobiprole resistance rate (12/102 isolates; MIC, ≥4 mg/liter). Epidemiological char...acterization demonstrated that the resistant isolates all belonged to different clones. Penicillin-binding protein (PBP) analysis showed substitutions in all PBPs and a novel insertion in PBP2a. The mecB and mecC genes were not detected. Ceftobiprole susceptibility screening is essential to avoid therapeutic failure and the spread of ceftobiprole-resistant strains.
Continua a leggere

Candidemia in the elderly: What does it change?
Anno: 2017
Rivista: PLOS ONE
Autori/autrici: Barchiesi, Francesco; Orsetti, Elena; Mazzanti, Sara; Trave, Francesca; Salvi, Aldo; Nitti, Cinzia; Manso, Esther
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/249423
Citazioni:
Candidemia in the elderly: What does it change? / Barchiesi, F., Orsetti, E., Mazzanti, S., Trave, F., Salvi, A., Nitti, C., Manso, E.. - In: PLOS ONE. - ISSN 1932-6203. - ELETTRONICO. - 12:5(2017), p. e0176576. [10.1371/journal.pone.0176576]
Abstract:
BACKGROUND: Candidemia is a life-threatening fungal infection and it can affect patients of all ages. Characterization of candidemia in the elderly is lacking. METHODS: We performed a retrospective study of adults (≥ 18 years) with candidemia diagnosed in our center in 2010-2015. Demograph...ics, comorbidities, clinical and microbiologic characteristics, antifungal treatment and outcome were compared between older (≤65 years) and younger (>65 years) patients. RESULTS: Among 302 patients with candidemia identified during the study period, 188 (62%) belonged to the elderly group. Comorbidities were significantly more frequent in older patients and included chronic pulmonary diseases, cardiovascular diseases, diabetes mellitus, and chronic renal failure (p ranging from <0.0001 to 0.017). A significantly higher proportion of older patients had septic shock (p = 0.040) at the time of candidemia. Candida albicans accounted for 53% of isolates and there were no significant differences between patients' age and Candida species. Thirty-day mortality was significantly higher in older (45%) than in younger (28%) patients (p = 0.003). Factors associated with a significant higher proportion of death in the elderly included older age (i.e.: old-old), being hospitalized in ICU rather than in other wards, suffering from chronic pulmonary diseases, the presence of septic shock, multiple organ failure, dialysis and being infected with C. glabrata (p ranging from <0.0001 to 0.034). On multivariate analysis septic shock (HR 1.744 [CI95% 1.049-2.898], p = 0.032) and multiple organ failure (HR 2.242 [CI95% 1.070-4.698], p = 0.032) were independently associated with a higher risk of death. The probability of 30-days survival of older patients was significantly reduced when compared to that of younger patients (p = 0.005) who did not receive any treatment. In the elderly, there was a trend toward higher MICs for fluconazole/C. albicans, fluconazole/C. glabrata, amphotericin B/C. albicans, and caspofungin/C. glabrata. CONCLUSIONS: In our study, we found that elderly patients with Candida bloodstream infections are characterized by a high mortality rate. In particular, the lack of any antifungal therapy as well as the occurrence of septic shock increased significantly the overall mortality. Additionally, we found that there was a trend of higher MIC for specific drug/Candida combination.
Continua a leggere

EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents
Anno: 2017
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Arendrup, Mc; Meletiadis, J; Howard, Sj; Mouton, J; Guinea, J; Lagrou, K; Arikan-Akdagli, S; Barchiesi, F; Hamal, P; Järv, H; Lass-Flörl, C; Mares, M; Matos, T; Muehlethaler, K; Rogers, Tr; Torp Andersen, C; Verweij, P.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/258221
Citazioni:
EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents / Arendrup, M.c., Meletiadis, J., Howard, S.j., Mouton, J., Guinea, J., Lagrou, K., Arikan-Akdagli, S., Barchiesi, F., Hamal, P., Järv, H., Lass-Flörl, C., Mares, M., Matos, T., Muehlethaler, K., Rogers, T.r., Torp Andersen, C., Verweij, P.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1469-0691. - ELETTRONICO. - 22:6 (571)(2017), pp. 1-4. [10.1016/j.cmi.2016.01.017]
Abstract:
The Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) has determined breakpoints for isavuconazole and Aspergillus and for itraconazole and Candida spp., released a new document summarizing existing and new min...imum inhibitory concentration ranges for quality control strains and revised the method documents for yeast and mould susceptibility testing. This technical note is based on the EUCAST isavuconazole and itraconazole rationale documents, version 1.0 of the routine and extended internal quality control for antifungal susceptibility testing as recommended by EUCAST, and the E.Def 7.3, E.Def 9.2 and E.Def 9.3 method documents (http://www.eucast.org).
Continua a leggere

Fungicidal activity and PK/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant C. parapsilosis candidemia.
Anno: 2017
Rivista: JOURNAL OF CHEMOTHERAPY
Autori/autrici: Tascini, C; Sozio, E; Di Paolo, A; Tintori, G; Leonildi, A; Bertolino, G; Carmassi, F; Tagliaferri, E; Menichetti, F; Barchiesi, F
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/258218
Citazioni:
Fungicidal activity and PK/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant C. parapsilosis candidemia / Tascini, C., Sozio, E., Di Paolo, A., Tintori, G., Leonildi, A., Bertolino, G., Carmassi, F., Tagliaferri, E., Menichetti, F., Barchiesi, F.. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1973-9478. - ELETTRONICO. - 29:6(2017), pp. 376-379. [10.1080/1120009X.2017.1289308]
Abstract:
Candida parapsilosis may be responsible for bloodstream infections (BSI) and it is characterised by an increased incidence of fluconazole resistance. A 75-year old woman with severe comorbidities received the insertion of a peripherally inserted central venous catheter. Fluconazole did not prevent a... C. parapsilosis BSI hence caspofungin was started after a nephrotoxic first-line treatment with amphotericin B. The ratio of peak plasma concentration over the minimum inhibitory concentration (Cmax/MIC) was adopted to maximise efficacy of caspofungin. MIC and plasma Cmax values were obtained by broth microdilution and LC-MS, respectively. Interestingly, daily doses of 1 mg/kg (total daily dose, 50 mg) allowed the achievement of Cmax/MIC values > 10. The optimised regimen was safe and effective, leading to negative blood culture at day 8. The patient was discharged home at day 21. Therefore, individualised dosing regimens of caspofungin may be effective and safe even in the case of C. parapsilosis BSI.
Continua a leggere

Aspergillus spp invasive external otitis: favourable outcome with a medical approach
Anno: 2016
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Marchionni, E; Parize, P; Lefevre, A; Vironneau, P; Bougnoux, M. E; Poiree, S; Coignard Biehler, H; Dewolf, S. E; Amazzough, K; Barchiesi, Francesco; Jullien, V; Alanio, A; Garcia Hermoso, D; Wassef, M; Kania, R; Lortholary, O; Lanternier, F.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/230451
Citazioni:
Aspergillus spp invasive external otitis: favourable outcome with a medical approach / Marchionni, E., Parize, P., Lefevre, A., Vironneau, P., Bougnoux, M.E., Poiree, S., Coignard Biehler, H., Dewolf, S.E., Amazzough, K., Barchiesi, F., Jullien, V., Alanio, A., Garcia Hermoso, D., Wassef, M., Kania, R., Lortholary, O., Lanternier, F.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - ELETTRONICO. - 22:5(2016), pp. 434-437. [10.1016/j.cmi.2015.12.027]
Abstract:
Aspergillus spp. invasive external otitis (IEO) is a rare infection. We performed a seven-year, single-centre retrospective study from 2007 to 2014 including all patients with proven Aspergillus spp. IEO. Twelve patients were identified. All patients had a poorly controlled diabetes mellitus and one... underwent solid organ transplant. The most frequently isolated species was A. flavus (n=10) and voriconazole was the first-line therapy in all cases, with a median length of treatment of 338.5 days [158-804]. None of the patients underwent extensive surgery. The clinical outcome was excellent. However, otologic sequelae were reported, including hearing impairment (n=7) and facial palsy (n=3).
Continua a leggere

Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014
Anno: 2016
Rivista: INFECTION
Autori/autrici: Barchiesi, Francesco; Orsetti, Elena; Gesuita, Rosaria; Skrami, Edlira; Manso, Esther
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/230456
Citazioni:
Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014 / Barchiesi, F., Orsetti, E., Gesuita, R., Skrami, E., Manso, E.. - In: INFECTION. - ISSN 0300-8126. - ELETTRONICO. - 44:2(2016), pp. 205-213. [10.1007/s15010-015-0845-z]
Abstract:
PURPOSE: We evaluated the epidemiology, clinical characteristics and outcome of candidemia in a single institution from 2010 to 2014. METHODS: A retrospective observational study of all cases of candidemia was carried out at a University Hospital in Central Italy including five intensive care... units (ICUs), 11 medical and 11 surgical wards. Data regarding demographic characteristics and clinical risk factors were collected from the patient's medical records. Antifungal susceptibility testing was performed and MIC results were interpreted according to species-specific clinical breakpoints. RESULTS: A total of 270 episodes of candidemia were identified. Overall incidence rate was 1.5 episodes/1000 hospital admissions. Although Candida albicans represented the most commonly isolated species, its percentage significantly decreased from 68 to 48 % (p = 0.040). The overall 30-day mortality was 35 %. The variables independently associated with a significant higher risk of mortality were: older age; being hospitalized in ICU or in medical wards vs surgical wards; being infected with C. albicans vs other species; the occurrence of septic shock, pneumonia and acute renal failure; the presence of a solid organ tumor or a chronic pulmonary disease. Conversely, an appropriate treatment was confirmed to be significantly associated with a lower risk of mortality. The overall resistance was low and it was noted only among triazoles. CONCLUSIONS: Our study shows that candidemia is a significant source of morbidity and mortality. The identification of risk factors associated with mortality along with the knowledge of local susceptibility may lead to a better management in terms of preventive and therapeutic measures.
Continua a leggere

Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection
Anno: 2016
Rivista: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Autori/autrici: Barchiesi, Francesco; Santinelli, Alfredo; Biscotti, Tommasina; Greganti, Gianfranco; Giannini, Daniele; Manso, Esther
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/247792
Citazioni:
Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection / Barchiesi, F., Santinelli, A., Biscotti, T., Greganti, G., Giannini, D., Manso, E.. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - STAMPA. - 71:8(2016), pp. 2230-2233. [10.1093/jac/dkw111]
Abstract:
OBJECTIVES: The aim of the present study was to evaluate the effects of delayed antifungal therapy on the outcome of invasive aspergillosis due to Aspergillus fumigatus in experimental models of infection. METHODS: A clinical isolate of A. fumigatus susceptible to amphotericin B (MIC 0.5 mg/L) ...and micafungin [minimum effective concentration (MEC) 0.03 mg/L] was used in all experiments. Two models of infection were investigated in immunosuppressed mice: disseminated infection and pulmonary infection. Twenty-four hours (early therapy) and 48 h (delayed therapy) post-infection, the mice were given vehicle, liposomal amphotericin B, micafungin or liposomal amphotericin B plus micafungin (combination). Drug efficacy was assessed by either survival or tissue burden experiments. RESULTS: In disseminated infection, any drug regimen given early significantly prolonged survival. When therapy was delayed, only micafungin and the combination were effective. In pulmonary infection, although there was a trend towards a prolongation of survival of mice treated early with liposomal amphotericin B, only the combination was effective. Similarly, when therapy was delayed, only the combination was effective. In disseminated infection, any drug regimen given early was effective at reducing the cfu in kidney tissue. In pulmonary infection, only liposomal amphotericin B and the combination given early were effective at reducing the cfu in lung tissue. Conversely, when therapy was delayed, no regimen was effective at reducing the tissue burden, regardless of the type of infection. CONCLUSIONS: Our data indicate that delayed initiation of antifungal therapy is deleterious in experimental models of invasive aspergillosis. A combination regimen seems to have some advantages over a single-drug approach when the therapy is started late.
Continua a leggere

Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients
Anno: 2016
Rivista: BMC INFECTIOUS DISEASES
Autori/autrici: Barchiesi, Francesco; Montalti, Roberto; Castelli, Pamela; Nicolini, Daniele; Staffolani, Silvia; Mocchegiani, Federico; Fiorentini, Alessandro; Manso, Esther; Vivarelli, Marco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/239996
Citazioni:
Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients / Barchiesi, F., Montalti, R., Castelli, P., Nicolini, D., Staffolani, S., Mocchegiani, F., Fiorentini, A., Manso, E., Vivarelli, M.. - In: BMC INFECTIOUS DISEASES. - ISSN 1471-2334. - STAMPA. - 16:1(2016), p. 538. [10.1186/s12879-016-1876-5]
Abstract:
Abstract BACKGROUND: Infections remain a leading cause of morbidity and mortality among liver transplant (LT) recipients. The aim of our study was to define the factors associated with outcome of early bacterial and fungal infections in a cohort of patients who underwent LT at the Universit...y Hospital of Ancona over a nine year period. METHODS: All consecutive patients who underwent LT in our center were considered. An early infection was defined as occurring in the first month post-transplantation. RESULTS: Among 330 patients who underwent LT from August 2005 to October 2014, 88 (27 %) had at least one infection documented within 30 days after transplantation. In 54 cases only one site was involved, in 34 cases ≥2 sites. There were 43 (30 %) pneumonia, 40 (27 %) surgical site infections, 31 (22 %) blood stream infections, and 30 (21 %) urinary tract infections. Gram-negative bacteria accounted for 64 % of the culture-positive cases, followed by Gram-positive bacteria (30 %) and fungi (6 %). A high proportion of drug-resistant strains was found within either Gram-negative (79 %) or Gram-positive (81 %) bacteria. There were 27 out 88 patients (31 %) who died within 180 days from the transplant. Factors independently associated with a higher risk of mortality were: renal replacement therapy (HR 11.797 [CI95 % 3.082-45.152], p < 0.0001), multisite infections (HR 4.865 [CI95 % 1.417-16.700], p = 0.012) and being infected with carbapenem-resistant Klebsiella pneumoniae (CRKP; HR 5.562 [CI95 % 1.186-26.088], p = 0.030). CONCLUSIONS: Overall, these data indicate that early infections in LT patients are characterized by significant mortality. In particular, an early infection caused by CRKP has an adverse impact on survival in these patients suggesting an urgent need for adopting preventive measures to avoiding this complication. KEYWORDS: Antibiotic resistance; Carbapenem-resistant Klebsiella pneumonaie; Early infections; Immunosuppression; Liver transplantation
Continua a leggere

Factors related to outcome of bloodstream infections due to Candida parapsilosis complex
Anno: 2016
Rivista: BMC INFECTIOUS DISEASES
Autori/autrici: Barchiesi, Francesco; Orsetti, Elena; Patrizia, Osimani; Catassi, Carlo; Fabio, Santelli; Ether, Manso .
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/249422
Citazioni:
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex / Barchiesi, F., Orsetti, E., Patrizia, O., Catassi, C., Fabio, S., Ether, M... - In: BMC INFECTIOUS DISEASES. - ISSN 1471-2334. - ELETTRONICO. - 16:1(2016), p. 387. [10.1186/s12879-016-1704-y]
Abstract:
BACKGROUND: Although Candida albicans is the most common cause of fungal blood stream infections (BSIs), infections due to Candida species other than C. albicans are rising. Candida parapsilosis complex has emerged as an important fungal pathogen and became one of the main causes of fungemia in s...pecific geographical areas. We analyzed the factors related to outcome of candidemia due to C. parapsilosis in a single tertiary referral hospital over a five-year period. METHODS: A retrospective observational study of all cases of candidemia was carried out at a 980-bedded University Hospital in Italy. Data regarding demographic characteristics and clinical risk factors were collected from the patient's medical records. Antifungal susceptibility testing was performed and MIC results were interpreted according to CLSI species-specific clinical breakpoints. RESULTS: Of 270 patients diagnosed with Candida BSIs during the study period, 63 (23 %) were infected with isolates of C. parapsilosis complex which represented the second most frequently isolated yeast after C. albicans. The overall incidence rate was 0.4 episodes/1000 hospital admissions. All the strains were in vitro susceptible to all antifungal agents. The overall crude mortality at 30 days was 27 % (17/63), which was significantly lower than that reported for C. albicans BSIs (42 % [61/146], p = 0.042). Being hospitalized in ICU resulted independently associated with a significant higher risk of mortality (HR 4.625 [CI95% 1.015-21.080], p = 0.048). Conversely, early CVC removal was confirmed to be significantly associated with a lower risk of mortality (HR 0.299 [CI95% 0.102-0.874], p = 0.027). Finally, the type of primary antifungal therapy did not influence the outcome of infection. CONCLUSIONS: Candidemia due to C. parapsilosis complex, the second most commonly causative agent of yeast BSIs in our center, is characterized by a non-negligible mortality at 30 days. An early CVC removal is associated with a significant reduced mortality.
Continua a leggere

Antiretroviral therapy management and rationalisation of available resources
Anno: 2015
Rivista: LE INFEZIONI IN MEDICINA
Autori/autrici: Cirioni, Oscar; Castelletti, Sefora; Ucciferri, Claudio; Falasca, Katia; Orsetti, Elena; Mazzocato, Susanna; Valeriani, Chiara; Di Campli, Francesco Maria; Barchiesi, Francesco; Vecchiet, Jacopo; Giacometti, Andrea
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/230453
Citazioni:
Antiretroviral therapy management and rationalisation of available resources / Cirioni, O., Castelletti, S., Ucciferri, C., Falasca, K., Orsetti, E., Mazzocato, S., Valeriani, C., Di Campli, F.M., Barchiesi, F., Vecchiet, J., Giacometti, A.. - In: LE INFEZIONI IN MEDICINA. - ISSN 1124-9390. - ELETTRONICO. - 23:4(2015), p. 330-5.
Abstract:
The treatment of HIV disease has led to a new division of management costs by shifting most of the necessary resources from inpatient treatment to outpatient management. Among the initiatives aimed at rationalising the resources available, we compared efficacy, tolerability and pharmacoeconomic impa...ct of different regimes of antiretroviral therapy (ART). The survey covered the first 50 patients, clinically stable and with good viro-immunological response, who switched in June 2012 from an ART based on the triple combination of tenofovir (TDF), emtricitabine (FTC) and a protease inhibitor boosted with ritonavir (PI/r) or a non-nucleoside reverse transcriptase inhibitor (NNRTI), to a treatment based on abacavir (ABC), lamivudine (3TC) and a PI/r or NNRTI. Of the 50 patients who operated the switch, 39 replaced a PI with nevirapine (NVP), for which the largest group of patients was treated with ABC + 3TC + NVP. On 31 May 2015, all patients completed the observation period of 96 weeks, with a mean observation period of 132 weeks and clinical-laboratory checks every four months. Laboratory analysis revealed an optimal maintenance of viral suppression and absolute and relative number of CD4 + lymphocytes and improving trend of creatinine, proteinuria, serum phosphate and bone alkaline phosphatase. There was a variable effect on lipids, with a drop in triglycerides associated with a modest increase in total cholesterol. Much of the HIV-positive population reporting to our hospitals (>50%) comprises individuals who have for years been in stable viraemic suppression, making a satisfactory immune recovery while in good overall clinical condition. This type of patient was the target of the present survey. At the end of 96 weeks of observation the new regimes were well tolerated and did not lead to viro-immunological or clinical deterioration. Pharmacoeconomic analysis showed better containment of the overall costs. No patient needed to be hospitalised during the observation period.
Continua a leggere

Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases
Anno: 2015
Rivista: LIVER TRANSPLANTATION
Autori/autrici: Barchiesi, Francesco; Mazzocato, Susanna; Mazzanti, Sara; Gesuita, Rosaria; Skrami, Edlira; Fiorentini, Alessro; Singh, Nina
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/230446
Citazioni:
Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases / Barchiesi, F., Mazzocato, S., Mazzanti, S., Gesuita, R., Skrami, E., Fiorentini, A., Singh, N.. - In: LIVER TRANSPLANTATION. - ISSN 1527-6465. - ELETTRONICO. - 21:2(2015), pp. 204-212. [10.1002/lt.24032]
Abstract:
nvasive aspergillosis (IA) in liver transplant recipients is associated with grave outcomes. We reviewed 116 individual cases reported in the literature from 1985 to 2013. IA was diagnosed after a median of 25 days after transplantation and involved a single organ in 51% of the cases, whereas in the... remaining cases, multiple sites were involved. The most common infecting Aspergillus species were Aspergillus fumigatus (73%), Aspergillus flavus (14%), and Aspergillus terreus (8%). Amphotericin B was the drug most frequently used, and it was followed by voriconazole and itraconazole. Combination regimens were used in 51% of the cases. The overall 1-year cumulative survival probability was 35% [95% confidence interval (CI) = 24.6%-49.6%]. Survival was significantly higher for patients reported from the year 2000 and thereafter (P < 0.001), for those diagnosed with IA more than 30 days after transplantation versus those diagnosed earlier (P = 0.019), and for patients without renal failure (P = 0.020). Additionally, the use of voriconazole was significantly associated with a higher probability of survival (P < 0.001). Cox regression analysis showed that subjects with the involvement of multiple sites had a 2.52 times higher risk of a negative outcome (95% CI = 1.08-5.87) than those with the involvement of a single site. Thus, IA causes life-threatening infections in liver transplant recipients. Predictors associated with poor outcomes may help clinicians to optimize the management of this infection.
Continua a leggere

Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature
Anno: 2015
Rivista: INFECTION
Autori/autrici: Mazzocato, Susanna; Marchionni, E.; Fothergill, A. W.; Sutton, D. A.; Staffolani, S.; Gesuita, Rosaria; Skrami, Edlira; Fiorentini, A.; Manso, E.; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/230469
Citazioni:
Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature / Mazzocato, S., Marchionni, E., Fothergill, A.W., Sutton, D.A., Staffolani, S., Gesuita, R., Skrami, E., Fiorentini, A., Manso, E., Barchiesi, F.. - In: INFECTION. - ISSN 0300-8126. - ELETTRONICO. - 43:2(2015), pp. 211-215. [10.1007/s15010-014-0668-3]
Abstract:
A case of systemic infection due to Saprochaete capitata in a patient with chronic lymphocytic leukemia is described. A review of the literature was conducted to identify all reported cases of this infection described between 1977 and August 2013. One hundred and four cases (included the present one...) were identified. The median age of the patients was 56 years and 56% were males. Comorbidities included acute myeloid leukemia (52%), acute lymphoid leukemia (22%), other hematological malignancies (13%) and non-hematological diseases (9%). At the time of the infection, 82% of the patients were neutropenic. In 75% of the cases, the yeast was isolated from blood culture, in 25% from other sterile sites. Empirical treatment was done in 36% of the cases. Fifty-eight percent of the individual cases were treated with a combination or a sequential antifungal therapy. Amphotericin B was the antifungal drug most commonly used, followed by voriconazole and itraconazole. The overall crude mortality was 60%. Saprochaete capitata causes life-threatening infections in neutropenic patients. This comprehensive literature review may help the clinician to optimize the management of this rare infection.
Continua a leggere

Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection.
Anno: 2014
Rivista: HEPATITIS MONTHLY
Autori/autrici: Brescini, Lucia; Orsetti, Elena; Gesuita, Rosaria; Piraccini, Francesca; Marchionni, Elisa; Staffolani, Silvia; Castelli, Pamela; Drenaggi, Davide; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/230415
Citazioni:
Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection / Brescini, L., Orsetti, E., Gesuita, R., Piraccini, F., Marchionni, E., Staffolani, S., Castelli, P., Drenaggi, D., Barchiesi, F.. - In: HEPATITIS MONTHLY. - ISSN 1735-143X. - ELETTRONICO. - (2014). [doi: 10.5812/hepatmon.15426]
Abstract:
BACKGROUND: Due to the high efficacy of combination antiretroviral therapy (cART), the number of patients living with HIV is increasing. Chronic HCV infection has become a leading cause of non-AIDS related morbidity and mortality in patients with HIV infection. OBJECTIVES: The aim of this cro...ss-sectional study was to identify factors associated with liver fibrosis (LF) in patients with HIV monoinfection and HIV-HCV coinfection. PATIENTS AND METHODS: We analyzed LF by transient elastometry ([TE], Fibroscan) in three groups of patients (HIV, HIV-HCV and HCV) followed at the Infectious Diseases Department of University of Ancona, Italy, between October 2009 and November 2012. RESULTS: In total, 354 adults including 98 HIV, 70 HIV-HCV and 186 HCV patients were studied. HIV-HCV patients had a longer duration of HIV (P < 0.006) and HCV (P < 0.001) infections. Additionally, they were receiving cART therapy for a longer period (P < 0.001); they had higher prevalence of lipodystrophy (P < 0.001) and higher HCV load (P = 0.004). LF was significantly more pronounced in HCV and HIV-HCV compared to HIV patients (P < 0.001). A total of 13.3%, 39.2% and 51.4% of HIV, HCV and HIV-HCV, respectively, showed a LF ≥ F2. Additionally, a severe LF (F = 4) was significantly more frequent among HIV-HCV compared to other groups. A longer exposure to didanosine, stavudine, lopinavir/ritonavir and fosamprenavir resulted in increased LF by univariate analysis (P ranging from < 0.001 to 0.007). By logistic regression analysis, the only variables significantly associated with increased LF were HCV coinfection, older age, and high AST values (P ranging from < 0.001 to 0.036). CONCLUSIONS: HCV coinfection, older age and AST were associated with LF in patients with HIV infection.
Continua a leggere

Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy
Anno: 2014
Rivista: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
Autori/autrici: Mazzotta, Elena; Tontodonati, Monica; Gabrielli, Chiara; Mazzocato, Susanna; Mazzetti, Marcello; Falasca, Katia; Cenderello, Giovanni; Vecchiet, Jacopo; Barchiesi, Francesco; Francisci, Daniela; Parruti, Giustino
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/230447
Citazioni:
Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy / Mazzotta, E., Tontodonati, M., Gabrielli, C., Mazzocato, S., Mazzetti, M., Falasca, K., Cenderello, G., Vecchiet, J., Barchiesi, F., Francisci, D., Parruti, G.. - In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. - ISSN 1758-2652. - ELETTRONICO. - 17:4(Suppl 3)(2014). [10.7448/IAS.17.4.19652]
Abstract:
INTRODUCTION: HIV infected patients have a higher risk of developing cancer than the general population. Kaposi's sarcoma, non-Hodgkin's lymphoma, primary CNS lymphoma and invasive cervical cancers are considered as AIDS defining [1]. An increased incidence in recent years has been repo...rted also for other malignancies after the introduction of cART [2,3]. MATERIALS AND METHODS: We performed a retrospective multicentric evaluation of all HIV infected patients with both AIDS and non-AIDS defining neoplasms at six Infectious Disease Units spread throughout Italy since 1991 through 2013. Cases were compared with equal number of controls without neoplasia followed at the same institutions, matched for length of HIV infection. RESULTS: Since 1991, 339 consecutive cases of malignancy were collected from the six convening centres, including approximately an equal proportion of AIDS (51.2%) and non-AIDS defining tumours. Mean prevalence of tumours among centres was 8.3% (r. 6.1%-9.6%). Mean age at tumour diagnosis was significantly lower than in controls (42.6±11.0 vs 46.8±10.6 years, respectively, p<0.0001). As to risk factors for HIV infection, approximately 1/4 (26.1%) of patients were drug abusers, in equal proportion as in controls. A remarkable higher proportion of cancer patients had CD4 T-cell counts <200 c/mmc at time of diagnosis (45.2% vs 13.3%, p<0.0001). Seventy percent of tumours occurred in males; 52.8% of tumour patients were diagnosed with AIDS before and 19.0% at the time of tumour diagnosis. Ninety (28.1%) tumour patients were dead at the time of data collection, a much higher proportion than among cases (12.9%, p<0.0001). Deaths among non-AIDS (20.8%) and AIDS defining tumour patients (35.0%) were significantly different (p=0.005). Predictors of AIDS defining tumours at the time of data collection were: male sex (57.9% vs 40.6%, p=0.004), CD4 T-cell counts <200 c/mmc (63.6% vs 44.1%, p<0.0001), whereas being cART treated at the time of tumour diagnosis was protective (38.0% vs 68.0%, p<0.0001). In the final multivariate model of logistic regression, male sex (OR=2.0, p=0.03) and not being cART treated (OR=2.5, p=0.001) held as independent predictors. CONCLUSIONS: Our retrospection revealed a considerably high proportion of non-AIDS defining tumours, apparently at rise in recent years. We registered high prevalence of tumours in each centre. Absence of cART seemed related with AIDS defining tumours: once more prevention of late presentation appeared the way to avoid worse prognosis in this setting.
Continua a leggere

Osteomyelitis caused by Aspergillusspecies: a review of 310 reported cases
Anno: 2014
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Gabrielli, E.; Fothergill, A. W.; Brescini, L.; Sutton, D. A.; Marchionni, E.; Orsetti, E.; Staffolani, S.; Castelli, P.; Gesuita, Rosaria; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/163757
Citazioni:
Osteomyelitis caused by Aspergillusspecies: a review of 310 reported cases / Gabrielli, E., Fothergill, A.W., Brescini, L., Sutton, D.A., Marchionni, E., Orsetti, E., Staffolani, S., Castelli, P., Gesuita, R., Barchiesi, F.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - ELETTRONICO. - 20:6(2014), pp. 559-565. [10.1111/1469-0691.12389]
Abstract:
Aspergillus osteomyelitis is a rare infection. We reviewed 310 individual cases reported in the literature from 1936 to 2013. The median age of patients was 43 years (range, 0-86 years), and 59% were males. Comorbidities associated with this infection included chronic granulomatous disease (19%), ha...ematological malignancies (11%), transplantation (11%), diabetes (6%), pulmonary disease (4%), steroid therapy (4%), and human immunodeficiency virus infection (4%). Sites of infection included the spine (49%), base of the skull, paranasal sinuses and jaw (18%), ribs (9%), long bones (9%), sternum (5%), and chest wall (4%). The most common infecting species were Aspergillus fumigatus (55%), Aspergillus flavus (12%), and Aspergillus nidulans (7%). Sixty-two per cent of the individual cases were treated with a combination of an antifungal regimen and surgery. Amphotericin B was the antifungal drug most commonly used, followed by itraconazole and voriconazole. Several combination or sequential therapies were also used experimentally. The overall crude mortality rate was 25%.
Continua a leggere

Reply to Ma et al.: Osteomyelitis caused by aspergillus species
Anno: 2014
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Gabrielli, E; Fothergill, A. W.; Brescini, Lucia; Sutton, D. A.; Marchionni, Edoardo; Orsetti, Elena; Staffolani, S.; Castelli, Pamela; Gesuita, Rosaria; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/230416
Citazioni:
Reply to Ma et al.: Osteomyelitis caused by aspergillus species / Gabrielli, E., Fothergill, A.W., Brescini, L., Sutton, D.A., Marchionni, E., Orsetti, E., Staffolani, S., Castelli, P., Gesuita, R., Barchiesi, F.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - ELETTRONICO. - 20:10(2014), p. O788. [10.1111/1469-0691.12613]

Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry
Anno: 2014
Rivista: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
Autori/autrici: Mazzocato, Susanna; Orsetti, Elena; Gesuita, Rosaria; Piraccini, Francesca; Drenaggi, Davide; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/230414
Citazioni:
Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry / Mazzocato, S., Orsetti, E., Gesuita, R., Piraccini, F., Drenaggi, D., Barchiesi, F.. - In: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. - ISSN 0036-5548. - ELETTRONICO. - 46:11(2014), pp. 797-802. [10.3109/00365548.2014.952245]
Abstract:
Monitoring of liver fibrosis (LF) is an essential tool for preventing liver-related complications in HIV/HCV co-infected patients. In this study, we compared LF progression by transient elastometry (TE) in 50 HIV/HCV co-infected and 115 HCV mono-infected patients followed in our institution between ...June 2006 and December 2011. Patients naive to interferon therapy and with at least two measurements of liver stiffness by TE were included. In all, 76% of HIV/HCV co-infected and 75% of HCV mono-infected patients remained in the same stage of LF over time. Conversely, 19% and 15% of HIV/HCV co-infected and HCV mono-infected subjects, respectively, had progression to advanced LF (≥ F3). Our study found a similar proportion of HIV/HCV co-infected and HCV mono-infected patients that developed an advanced LF during the follow-up time considered. Alcohol abuse was the only factor significantly associated with the progression as evidenced by multiple quantile regression analysis.
Continua a leggere

In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes
Anno: 2014
Rivista: MYCOSES
Autori/autrici: Simonetti, Oriana; Silvestri, Carmela; Arzeni, Daniela; Cirioni, Oscar; Kamysz, Wojciech; Conte, Irene; Staffolani, Silvia; Orsetti, Elena; Morciano, Angela; Castelli, Pamela; Scalise, Alessandro; Kamysz, Elzbieta; Offidani, Annamaria; Giacometti, Andrea; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/205739
Citazioni:
In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes / Simonetti, O., Silvestri, C., Arzeni, D., Cirioni, O., Kamysz, W., Conte, I., Staffolani, S., Orsetti, E., Morciano, A., Castelli, P., Scalise, A., Kamysz, E., Offidani, A., Giacometti, A., Barchiesi, F.. - In: MYCOSES. - ISSN 0933-7407. - STAMPA. - 57:4(2014), pp. 233-239. [10.1111/myc.12148]

Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis.
Anno: 2013
Rivista: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Autori/autrici: Barchiesi, Francesco; Spreghini, Elisabetta; Sanguinetti, M; Giannini, Daniele; Manso, E; Castelli, P; Girmenia, C.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/163733
Citazioni:
Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis / Barchiesi, F., Spreghini, E., Sanguinetti, M., Giannini, D., Manso, E., Castelli, P., Girmenia, C.. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - STAMPA. - 68:11(2013), pp. 2587-2591. [10.1093/jac/dkt232]
Abstract:
Abstract OBJECTIVES: The aim of the present study was to evaluate the effects of amphotericin B (AMB) on clinical isolates of Aspergillus flavus. METHODS: MICs of both standard AMB and liposomal AMB (L-AMB) were determined using a broth dilution method for seven isolates of A. flavus. AMB MICs were ...also determined using the Etest. The activity of the polyene was then investigated in a murine model of systemic aspergillosis in which animals were infected intravenously, treated intravenously with several doses of the polyene (1-10 mg/kg/day) and observed for survival. RESULTS: Broth dilution AMB, broth dilution L-AMB and Etest AMB MICs ranged from 0.5 to 2.0 mg/L, 0.06 to >16 mg/L and 1.0 to >32 mg/L, respectively. There were two isolates for which all doses were effective at prolonging the survival. Their AMB MICs were ≤1.0 mg/L, regardless of the method/drug formulation utilized for testing. There were four isolates for which no regimen was effective. Their broth dilution AMB, broth dilution L-AMB and Etest AMB MICs ranged from 1.0 to 2.0 mg/L, 0.06 to >16 mg/L and 2.0 to >32 mg/L, respectively. There was one isolate for which only L-AMB given at 10 mg/kg/day was effective; broth dilution MICs of AMB and L-AMB were 0.5 mg/L, while the Etest MIC of AMB was 2.0 mg/L. CONCLUSIONS: Our data indicate that not all isolates of A. flavus should be considered resistant to AMB. The Etest represented the in vitro method that best correlated with the experimental infection. Finally, a clinical isolate showing an MIC ≥2.0 mg/L may be reasonably considered resistant in vivo to any dose/formulation of the polyene.
Continua a leggere

SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients.
Anno: 2013
Rivista: INFECTION
Autori/autrici: Montagna, Mt; Lovero, G; Coretti, C; Martinelli, D; Delia, M; De Giglio, O; Caira, M; Puntillo, F; D'Antonio, D; Venditti, M; Sambri, V; Di Bernardo, F; Barbui, A; Lo Cascio, G; Concia, E; Mikulska, M; Viscoli, C; Maximova, N; Candoni, A; Oliveri, S; Lombardi, G; Pitzurra, L; Sanguinetti, M; Masciari, R; Santantonio, T; Andreoni, S; Barchiesi, Francesco; Pecile, P; Farina, C; Viale, P; Specchia, G; Caggiano, G; Pagano, L.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/163732
Citazioni:
SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients / Montagna, M.t., Lovero, G., Coretti, C., Martinelli, D., Delia, M., De Giglio, O., Caira, M., Puntillo, F., D'Antonio, D., Venditti, M., Sambri, V., Di Bernardo, F., Barbui, A., Lo Cascio, G., Concia, E., Mikulska, M., Viscoli, C., Maximova, N., Candoni, A., Oliveri, S., et al.. - In: INFECTION. - ISSN 0300-8126. - STAMPA. - 42:1(2013), pp. 141-151. [10.1007/s15010-013-0539-3]
Abstract:
Abstract PURPOSE: We compared the risk factors, the diagnostic tools and the outcome of filamentous fungal infections (FFIs) in hematological patients (HAEs) and non-hematological patients (non-HAEs). METHODS: Prospective surveillance (2009-2011) of proven and probable FFIs was implemented in 23... Italian hospitals. RESULTS: Out of 232 FFIs, 113 occurred in HAEs and 119 in non-HAEs. The most frequent infection was invasive aspergillosis (76.1 % for HAEs, 56.3 % for non-HAEs), and the localization was principally pulmonary (83.2 % for HAEs, 74.8 % for non-HAEs). Neutropenia was a risk factor for 89.4 % HAEs; the main underlying condition was corticosteroid treatment (52.9 %) for non-HAEs. The distribution of proven and probable FFIs was different in the two groups: proven FFIs occurred more frequently in non-HAEs, whereas probable FFIs were correlated with the HAEs. The sensitivity of the galactomannan assay was higher for HAEs than for non-HAEs (95.3 vs. 48.1 %). The overall mortality rate was 44.2 % among the HAEs and 35.3 % among the non-HAEs. The etiology influenced the patient outcomes: mucormycosis was associated with a high mortality rate (57.1 % for HAEs, 77.8 % for non-HAEs). CONCLUSIONS: The epidemiological and clinical data for FFIs were not identical in the HAEs and non-HAEs. The differences should be considered to improve the management of FFIs according to the patients' setting.
Continua a leggere

Molecular epidemiology of Italian clinical Cryptococcus neoformans var. grubii isolates
Anno: 2013
Rivista: MEDICAL MYCOLOGY
Autori/autrici: Cogliati, Massimo; Zamfirova, Ralika R.; Tortorano, Anna Maria; Viviani, Maria Anna; The Fimua Cryptococcosis, Network; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/230471
Citazioni:
Molecular epidemiology of Italian clinical Cryptococcus neoformans var. grubii isolates / Cogliati, M., Zamfirova, R.R., Tortorano, A.M., Viviani, M.A., The Fimua Cryptococcosis, N., Barchiesi, F.. - In: MEDICAL MYCOLOGY. - ISSN 1369-3786. - ELETTRONICO. - 51:5(2013), pp. 499-506. [10.3109/13693786.2012.751642]
Abstract:
Cryptococcus neoformans variety grubii is the major etiological agent of cryptococcal meningitis in both immunocompromised and immunocompetent patients. The current PCR-based molecular methods are not sufficient to discriminate among the different populations of this yeast. Therefore, the aim of the... present study was to investigate the genotypes of the Italian clinical C. neoformans var. grubii isolates by multilocus sequence typing (MLST). A total of 53 isolates, each representative of a single case, were studied. Genotyping was performed using the ISHAM Cryptococcus MLST consensus scheme and the results were compared to the publically available global C. neoformans var. grubii MLST dataset. A total of 16 genotypes were identified; 14 were new genotypes, one was identical to sequence type (ST) ST81, which had been previously reported from Thailand, and one to ST23 already identified in Uganda, the USA and Korea. Sequence type ST61 was the most numerous, including 16 isolates. Network phylogenetic analysis showed that the Italian isolates could be divided into at least three clusters with similarities with those recovered in Africa, Asia and Americas. Distribution of the STs among the isolates could not be correlated to the hospital in which they were recovered or to the HIV status of the patients. The majority of the isolates belonged to the molecular type VNI; three belonged to the rare molecular type VNII and one to the VNB group, which until now had not been described in Europe. The results reveal that the Italian C. neoformans var. grubii population presents a distinct variability, displaying a high number of new genotypes, and probably recombines sexually.
Continua a leggere

Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report.
Anno: 2013
Rivista: WEST INDIAN MEDICAL JOURNAL
Autori/autrici: Cirioni, Oscar; Weimer, Liliana E; Fragola, Vincenzo; Giacometti, Andrea; Gabrielli, Eleonora; Marchionni, Elisa; Massella, M; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/230417
Citazioni:
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report / Cirioni, O., Weimer, L.E., Fragola, V., Giacometti, A., Gabrielli, E., Marchionni, E., Massella, M., Barchiesi, F.. - In: WEST INDIAN MEDICAL JOURNAL. - ISSN 0043-3144. - ELETTRONICO. - (2013). [10.7727/WIMJ.2011.193.]
Abstract:
Sustained increase of serum creatine phosphokinase (CPK) concentrations and muscle abnormalities have been reported in patients taking raltegravir (RAL). In this report, we describe a case of sustained and asymptomatic increase of serum CPK concentrations associated with raltegravir, zidovudine, and... lamivudine in an HIV-1 experienced patient with intolerance to protease inhibitor, abacavir and penicillin during 32 weeks of continuous drug monitoring.
Continua a leggere

Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals
Anno: 2013
Rivista: INFECTION
Autori/autrici: Orsetti, E.; Staffolani, S.; Gesuita, Rosaria; Iaco, G.; Marchionni, E.; Brescini, L.; Castelli, P.; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/163759
Citazioni:
Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals / Orsetti, E., Staffolani, S., Gesuita, R., Iaco, G., Marchionni, E., Brescini, L., Castelli, P., Barchiesi, F.. - In: INFECTION. - ISSN 0300-8126. - 41:(2013), pp. 987-990. [10.1007/s15010-013-0465-4]
Abstract:
BACKGROUND: Chronic hepatitis C virus (HCV) infection has become a leading cause of non-acquired immunodeficiency syndrome (AIDS)-related morbidity and mortality for human immunodeficiency virus (HIV)-infected persons in the highly active antiretroviral therapy (HAART) era. Despite injection drug ...use (IDU) remaining the main route of HCV infection, recent reports indicate outbreaks of acute HCV infection among HIV-infected men who have sex with men (MSM) and sexually transmitted infections in the absence of IDU. METHODS: We conducted a retrospective observational study of behavioural and demographic factors of patients with and without incident HCV infection among HIV-infected individuals followed at the AIDS Clinic of the Infectious Disease Department of the University of Ancona from 1989 to 2011. RESULTS: Overall, 440 patients were considered; a total of 145 patients had initial positive HCV antibody test results (HCV+); a total of 295 patients had initial negative HCV antibody test results (HCV-). In the latter population, 14 seroconverted to HCV antibody (neoHCV), with an overall incidence of 0.59 per 100 person-years. While IDU was the principal risk factor of HCV+, the main route of transmission of incident HCV infection was sexual transmission. The HCV- group was significantly older than the other two groups and showed a significantly lower CD4 count at HIV diagnosis than neoHCV. Being Italian and having a low level of education were significantly more represented in HCV+. Younger age at HIV infection, IDU and additional risk factors other than sexual transmission significantly affected the probability of being HCV+. The cumulative probability of developing HCV infection in the HCV- group was calculated to be 6% at 15 years. CONCLUSIONS: The epidemiology of the newly acquired HCV in HIV+ persons is changing. Therefore, a frequent and constant counselling about HCV infection is desirable and a periodical screening test is mandatory.
Continua a leggere

In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
Anno: 2012
Rivista: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Autori/autrici: Spreghini, E; Orlando, F; Tavanti, A; Senesi, S; Giannini, D; Manso, E; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75296
Citazioni:
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis / Spreghini, E., Orlando, F., Tavanti, A., Senesi, S., Giannini, D., Manso, E., Barchiesi, F.. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - (2012). [10.1093/jac/dks180]

Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata
Anno: 2012
Rivista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Autori/autrici: Spreghini, E.; Orlando, F.; Sanguinetti, M.; Posteraro, B.; Giannini, D.; Manso, E.; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/66076
Citazioni:
Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata / Spreghini, E., Orlando, F., Sanguinetti, M., Posteraro, B., Giannini, D., Manso, E., Barchiesi, F.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 56/2012:3(2012), pp. 1215-1222. [10.1128/AAC.05872-11]

Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates.
Anno: 2012
Rivista: MYCOPATHOLOGIA
Autori/autrici: Cogliati, M; Barchiesi, Francesco; Spreghini, E; Tortorano, Am
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75418
Citazioni:
Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates / Cogliati, M., Barchiesi, F., Spreghini, E., Tortorano, A.m.. - In: MYCOPATHOLOGIA. - ISSN 0301-486X. - 173:(2012), pp. 347-357. [10.1007/s11046-011-9467-x]

EUCAST technical note on posaconazole.
Anno: 2011
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Arendrup, Mc; Hope, Ww; Lass Flörl, C; Cuenca Estrella, M; Arikan, S; Barchiesi, Francesco; Bille, J; Chryssanthou, E; Dannaoui, E; Gaustad, P; Järv, H; Klimko, N; Moore, Cb; Schmalreck, A; Velegraki, A; Verweij, P.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75420
Citazioni:
EUCAST technical note on posaconazole / Arendrup, M.c., Hope, W.w., Lass Flörl, C., Cuenca Estrella, M., Arikan, S., Barchiesi, F., Bille, J., Chryssanthou, E., Dannaoui, E., Gaustad, P., Järv, H., Klimko, N., Moore, C.b., Schmalreck, A., Velegraki, A., Verweij, P.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - 17:(2011), pp. E16-E17. [10.1111/j.1469-0691.2011.03646.x]
Abstract:
Lavoro multicentrico europeo (EUCAST - EURropean Committee for Antifungal Susceptibility Testing)

In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinica isolates of Candida spp
Anno: 2011
Rivista: PEPTIDES
Autori/autrici: Kamysz, E; Simonetti, Oriana; Cirioni, Oscar; Arzeni, D; Ganzetti, G; Campanati, Anna; Giacometti, Andrea; Gabrielli, E; Silvestri, C; Kamysz, W; Offidani, Annamaria; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/55657
Citazioni:
In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinica isolates of Candida spp / Kamysz, E., Simonetti, O., Cirioni, O., Arzeni, D., Ganzetti, G., Campanati, A., Giacometti, A., Gabrielli, E., Silvestri, C., Kamysz, W., Offidani, A., Barchiesi, F.. - In: PEPTIDES. - ISSN 0196-9781. - 32:(2011), pp. 99-103.
Abstract:
2010 Nov 3. [Epub ahead of print]

Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients.
Anno: 2011
Rivista: TRANSPLANTATION PROCEEDINGS
Autori/autrici: Grossi, Pa; Gasperina, Dd; Barchiesi, Francesco; Biancofiore, G; Carafiello, G; De Gasperi, A; Sganga, G; Menichetti, F; Montagna, Mt; Pea, F; Venditti, M; Viale, P; Viscoli, C; Nanni Costa, A.
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75417
Citazioni:
Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients / Grossi, P.a., Gasperina, D.d., Barchiesi, F., Biancofiore, G., Carafiello, G., De Gasperi, A., Sganga, G., Menichetti, F., Montagna, M.t., Pea, F., Venditti, M., Viale, P., Viscoli, C., Nanni Costa, A.. - In: TRANSPLANTATION PROCEEDINGS. - ISSN 0041-1345. - 43:(2011). [10.1016/j.transproceed.2011.06.020]

EUCAST technical note on anidulafungin
Anno: 2011
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Arendrup, Mc; Hope, Ww; Lass Flörl, C; Cuenca Estrella, M; Arikan, S; Barchiesi, Francesco; Bille, J; Chryssanthou, E; Dannaoui, E; Gaustad, P; Järv, H; Klimko, N; Moore, Cb; Schmalreck, A; Velegraki, A; Verweij, P.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/72200
Citazioni:
EUCAST technical note on anidulafungin / Arendrup, M.c., Hope, W.w., Lass Flörl, C., Cuenca Estrella, M., Arikan, S., Barchiesi, F., Bille, J., Chryssanthou, E., Dannaoui, E., Gaustad, P., Järv, H., Klimko, N., Moore, C.b., Schmalreck, A., Velegraki, A., Verweij, P.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - 17/2011:11(2011), pp. E18-E20. [10.1111/j.1469-0691.2011.03647.x]
Abstract:
EUCAST - lavoro collaborativo (EUropean Committee for Antifungal Susceptibility Testing)

EUCAST technical note on Amphotericin B
Anno: 2011
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Arendrup, Mc; Hope, Ww; Lass-Flörl, C; Cuenca-Estrella, M; Arikan, S; Barchiesi, F; Bille, J; Chryssanthou, E; Dannaoui, E; Gaustad, P; Järv, H; Klimko, N; Moore, Cb; Schmalreck, A; Velegraki, A; Verweij, P.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/71910
Citazioni:
EUCAST technical note on Amphotericin B / Arendrup, M.c., Hope, W.w., Lass-Flörl, C., Cuenca-Estrella, M., Arikan, S., Barchiesi, F., Bille, J., Chryssanthou, E., Dannaoui, E., Gaustad, P., Järv, H., Klimko, N., Moore, C.b., Schmalreck, A., Velegraki, A., Verweij, P.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - 17:12(2011), pp. E27-E29. [10.1111/j.1469-0691.2011.03644.x]
Abstract:
Lavoro multicentrico internazionale europeo - EUCAST (european commitee for antifungal susceptibility testing)

Disruption of homocitrate synthase genes in Candida albicans affects growth but not virulence.
Anno: 2010
Rivista: MYCOPATHOLOGIA
Autori/autrici: Kur, K; Gabriel, I; Morschhäuser, J; Barchiesi, Francesco; Spreghini, Elisabetta; Milewski, S.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75415
Citazioni:
Disruption of homocitrate synthase genes in Candida albicans affects growth but not virulence / Kur, K., Gabriel, I., Morschhäuser, J., Barchiesi, F., Spreghini, E., Milewski, S.. - In: MYCOPATHOLOGIA. - ISSN 0301-486X. - 170:(2010), pp. 397-402. [10.1007/s11046-010-9337-y]
Abstract:
Biologia molecolare / Modelli sperimentali di infezione da lieviti

In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.
Anno: 2010
Rivista: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Autori/autrici: Spreghini, Elisabetta; Orlando, F; Giannini, Daniele; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75416
Citazioni:
In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility / Spreghini, E., Orlando, F., Giannini, D., Barchiesi, F.. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - 65:(2010), pp. 2158-2163. [10.1093/jac/dkq276]

In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes.
Anno: 2009
Rivista: BRITISH JOURNAL OF DERMATOLOGY
Autori/autrici: Simonetti, Oriana; Arzeni, D; Ganzetti, G; Silvestri, C; Cirioni, Oscar; Gabrielli, E; Castelletti, S; Kamysz, W; Kamysz, E; Scalise, G; Offidani, Annamaria; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/55663
Citazioni:
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes / Simonetti, O., Arzeni, D., Ganzetti, G., Silvestri, C., Cirioni, O., Gabrielli, E., Castelletti, S., Kamysz, W., Kamysz, E., Scalise, G., Offidani, A., Barchiesi, F.. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - 16:(2009), pp. 249-252.

In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents.
Anno: 2009
Rivista: MEDICAL MYCOLOGY
Autori/autrici: Barchiesi, Francesco; Silvestri, Carmela; Arzeni, D.; Ganzetti, Giulia; Castelletti, S.; Simonetti, Oriana; Cirioni, Oscar; Kamysz, W.; Kamysz, E.; Spreghini, E.; Abruzzetti, A.; Riva, A.; Offidani, Annamaria; Giacometti, Andrea; Scalise, Giorgio
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/50175
Citazioni:
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents / Barchiesi, F., Silvestri, C., Arzeni, D., Ganzetti, G., Castelletti, S., Simonetti, O., Cirioni, O., Kamysz, W., Kamysz, E., Spreghini, E., Abruzzetti, A., Riva, A., Offidani, A., Giacometti, A., Scalise, G.. - In: MEDICAL MYCOLOGY. - ISSN 1369-3786. - 47:(2009), pp. 321-326. [10.1080/13693780802641920]

Anidulafungin in combination with amphotericin B against Aspergillus fumigatus.
Anno: 2009
Rivista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Autori/autrici: Spreghini, E; Orlando, F; Santinelli, Alfredo; Pisa, E; Loretelli, C; Manso, E; Milici, Me; Scalise, G; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75414
Citazioni:
Anidulafungin in combination with amphotericin B against Aspergillus fumigatus / Spreghini, E., Orlando, F., Santinelli, A., Pisa, E., Loretelli, C., Manso, E., Milici, M.e., Scalise, G., Barchiesi, F.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 53:(2009), pp. 4035-4039. [10.1128/AAC.00659-09]

In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes.
Anno: 2009
Rivista: PEPTIDES
Autori/autrici: Simonetti, Oriana; Ganzetti, Giulia; Arzeni, D; Campanati, Anna; Marconi, B; Silvestri, Carmela; Cirioni, Oscar; Gabrielli, E; Lenci, I; Kamysz, W; Kamysz, E; Giacometti, Andrea; Scalise, G; Barchiesi, Francesco; Offidani, Annamaria
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75915
Citazioni:
In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes / Simonetti, O., Ganzetti, G., Arzeni, D., Campanati, A., Marconi, B., Silvestri, C., Cirioni, O., Gabrielli, E., Lenci, I., Kamysz, W., Kamysz, E., Giacometti, A., Scalise, G., Barchiesi, F., Offidani, A.. - In: PEPTIDES. - ISSN 0196-9781. - 30:10(2009), pp. 1794-1797. [10.1016/j.peptides.2009.06.033]

In vitro activity of the lipopetide derivative (Pal-lys-lysNh2), alone and in combination with antifungal agents, against clinical isolates of dermatophytes
Anno: 2009
Rivista: BRITISH JOURNAL OF DERMATOLOGY
Autori/autrici: Simonetti, Oriana; Arzeni, D; Ganzetti, Giulia; Silvestri, C; Cirioni, Oscar; Gabrielli, E; Castelletti, S; Kamysz, W; Kamysz, E; Scalise, G; Offidani, Annamaria; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/35668
Citazioni:
In vitro activity of the lipopetide derivative (Pal-lys-lysNh2), alone and in combination with antifungal agents, against clinical isolates of dermatophytes / Simonetti, O., Arzeni, D., Ganzetti, G., Silvestri, C., Cirioni, O., Gabrielli, E., Castelletti, S., Kamysz, W., Kamysz, E., Scalise, G., Offidani, A., Barchiesi, F.. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - 161(2):2(2009), pp. 249-252. [10.1111/j.1365-2133.2009.09166.x]

Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
Anno: 2008
Rivista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Autori/autrici: Spreghini, E; Maida, Cm; Tomassetti, S; Orlando, F; Giannini, D; Milici, Me; Scalise, G; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/30474
Citazioni:
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole / Spreghini, E., Maida, C.m., Tomassetti, S., Orlando, F., Giannini, D., Milici, M.e., Scalise, G., Barchiesi, F.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 52:(2008), pp. 1929-1933. [10.1128/AAC.00130-08]

EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.
Anno: 2008
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Rodriquez Tudela, Jl; Donnelly, Jp; Arendrup, Mc; Arikan, S; Barchiesi, Francesco; Bille, J; Chryssanthou, E; Cuenca Estrella, M; Dannaoui, E; Denning, D; Fegeler, W; Gaustad, P; Lass Flörl, C; Moore, C; Richardson, M; Schmalreck, A; Velegraki, A; Verweij, P.
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75411
Citazioni:
EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds / Rodriquez Tudela, J.l., Donnelly, J.p., Arendrup, M.c., Arikan, S., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca Estrella, M., Dannaoui, E., Denning, D., Fegeler, W., Gaustad, P., Lass Flörl, C., Moore, C., Richardson, M., Schmalreck, A., Velegraki, A., Verweij, P.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - 14:(2008), pp. 982-984. [10.1111/j.1469-0691.2008.02086.x]

EUCAST technical note on fluconazole.
Anno: 2008
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Rodriquez Tudela, Jl; Donnelly, Jp; Arendrup, Mc; Arikan, S; Barchiesi, Francesco; Bille, J; Chryssanthou, E; Cuenca Estrella, M; Dannaoui, E; Denning, D; Fegeler, W; Gaustad, P; Klimko, N; Lass Flörl, C; Moore, C; Richardson, M; Schmalreck, A; Stenderup, J; Velegraki, A; Verweij, P.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75408
Citazioni:
EUCAST technical note on fluconazole / Rodriquez Tudela, J.l., Donnelly, J.p., Arendrup, M.c., Arikan, S., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca Estrella, M., Dannaoui, E., Denning, D., Fegeler, W., Gaustad, P., Klimko, N., Lass Flörl, C., Moore, C., Richardson, M., Schmalreck, A., Stenderup, J., Velegraki, A., Verweij, P.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - 14:(2008), pp. 193-195. [10.1111/j.1469-0691.2007.01899.x]

Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
Anno: 2008
Rivista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Autori/autrici: Spreghini, E; Maida, Cm; Milici, Me; Scalise, G; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75407
Citazioni:
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B / Spreghini, E., Maida, C.m., Milici, M.e., Scalise, G., Barchiesi, F.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 52:(2008), pp. 513-517. [10.1128/AAC.01447-07]

EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts.
Anno: 2008
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Rodriguez Tudela, Jl; Arendrup, Mc; Barchiesi, Francesco; Bille, J; Chryssanthou, E; Cuenca Estrella, M; Dannaoui, E; Denning, Dw; Donnelly, Jp; Dromer, F; Fegeler, W; Lass Flörl, C; Moore, C; Richardson, M; Sandven, P; Velegraki, A; Verweij, P.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75409
Citazioni:
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts / Rodriguez Tudela, J.l., Arendrup, M.c., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca Estrella, M., Dannaoui, E., Denning, D.w., Donnelly, J.p., Dromer, F., Fegeler, W., Lass Flörl, C., Moore, C., Richardson, M., Sandven, P., Velegraki, A., Verweij, P.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - 14:(2008), pp. 398-405. [10.1111/j.1469-0691.2007.01935.x]

EUCAST Technical Note on voriconazole.
Anno: 2008
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Rodriguez Tudela, Jl; Donnelly, Jp; Arendrup, Mc; Arikan, S; Barchiesi, Francesco; Bille, J; Chryssanthou, E; Cuenca Estrella, M; Dannaoui, E; Denning, D; Fegeler, W; Gaustad, P; Lass Flörl, C; Moore, C; Richardson, M; Schmalreck, A; Velegraki, A; Verweij, P.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75412
Citazioni:
EUCAST Technical Note on voriconazole / Rodriguez Tudela, J.l., Donnelly, J.p., Arendrup, M.c., Arikan, S., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca Estrella, M., Dannaoui, E., Denning, D., Fegeler, W., Gaustad, P., Lass Flörl, C., Moore, C., Richardson, M., Schmalreck, A., Velegraki, A., Verweij, P.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - 14:(2008), pp. 985-987. [10.1111/j.1469-0691.2008.02087.x]

Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi.
Anno: 2008
Rivista: JOURNAL OF CLINICAL MICROBIOLOGY
Autori/autrici: Maida, Cm; Milici, Me; Trovato, L; Oliveri, S; Amodio, E; Spreghini, E; Scalise, G; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/30473
Citazioni:
Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi / Maida, C.m., Milici, M.e., Trovato, L., Oliveri, S., Amodio, E., Spreghini, E., Scalise, G., Barchiesi, F.. - In: JOURNAL OF CLINICAL MICROBIOLOGY. - ISSN 0095-1137. - 46:(2008), pp. 4071-4074. [10.1128/JCM.01088-08]

In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp.
Anno: 2007
Rivista: JOURNAL OF CHEMOTHERAPY
Autori/autrici: Barchiesi, Francesco; Giacometti, Andrea; Cirioni, Oscar; Arzeni, D; Kamysz, W; Silvestri, C; Licci, A; Riva, A; Marigliano, A; DELLA VITTORIA, A; Nadolski, P; Ukasiak, J; Scalise, G.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/36161
Citazioni:
In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp / Barchiesi, Francesco; Giacometti, Andrea; Cirioni, Oscar; Arzeni, D; Kamysz, W; Silvestri, C; Licci, A; Riva, A; Marigliano, A; DELLA VITTORIA, A; Nadolski, P; Ukasiak, J; Scalise, G.. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - 19:(2007), pp. 514-518.

In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans.
Anno: 2007
Rivista: PEPTIDES
Autori/autrici: Barchiesi, Francesco; Giacometti, Andrea; Cirioni, O; Arzeni, D; Silvestri, C; Kamysz, W; Abbruzzetti, A; Riva, A; Kamysz, E; Scalise, G.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/30472
Citazioni:
In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans / Barchiesi, F., Giacometti, A., Cirioni, O., Arzeni, D., Silvestri, C., Kamysz, W., Abbruzzetti, A., Riva, A., Kamysz, E., Scalise, G.. - In: PEPTIDES. - ISSN 0196-9781. - 28:(2007), pp. 1509-1513.

Comparison between Disk Diffusion and Microdilution Methods for Determining Susceptibility of Clinical Yeast Isolates to Caspofungin.
Anno: 2007
Rivista: JOURNAL OF CLINICAL MICROBIOLOGY
Autori/autrici: Milici, Me; Maida, Cm; Spreghini, E; Ravazzolo, B; Oliveri, S; Scalise, G; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/30469
Citazioni:
Comparison between Disk Diffusion and Microdilution Methods for Determining Susceptibility of Clinical Yeast Isolates to Caspofungin / Milici, M.e., Maida, C.m., Spreghini, E., Ravazzolo, B., Oliveri, S., Scalise, G., Barchiesi, F.. - In: JOURNAL OF CLINICAL MICROBIOLOGY. - ISSN 0095-1137. - Aug 29; [Epub ahead of print]:(2007).

Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin.
Anno: 2007
Rivista: JOURNAL OF CLINICAL MICROBIOLOGY
Autori/autrici: Milici, Me; Maida, Cm; Spreghini, E; Ravazzolo, B; Oliveri, S; Scalise, G; Barchiesi, Francesco
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75406
Citazioni:
Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin / Milici, M.e., Maida, C.m., Spreghini, E., Ravazzolo, B., Oliveri, S., Scalise, G., Barchiesi, F.. - In: JOURNAL OF CLINICAL MICROBIOLOGY. - ISSN 0095-1137. - 45:(2007), pp. 3529-3533. [10.1128/JCM.00826-07]
Abstract:
We compared the caspofungin (CAS) susceptibility testing results generated by the disk diffusion (DD) assay with the results of the Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BD) reference method for 106 yeast isolates. The isolates represented 11 different fungal specie...s, including Candida albicans (n = 50), C. parapsilosis (n = 10), C. glabrata (n = 10), C. tropicalis (n = 10), C. guillermondii (n = 6), C. rugosa (n = 5), C. krusei (n = 5), C. kefyr (n = 2), C. pelliculosa (n = 2), Saccharomyces cerevisiae (n = 3), and Geotrichum candidum (n = 3). The DD assay was performed in supplemented Mueller-Hinton agar with CAS, which was tested at concentrations of 2, 10, and 25 mug per disk. MICs and inhibition zone diameters were evaluated at 24 and 48 h. In general, the results obtained by the DD assay correlated well with those obtained by the BD method. In particular, a significant correlation between methods was observed when CAS was used at concentration of 2 mug/disk at a reading time of either 24 or 48 h.
Continua a leggere

Posaconazole prophylaxis in experimental systemic zygomycosis.
Anno: 2007
Rivista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Autori/autrici: Barchiesi, Francesco; Spreghini, E.; Santinelli, Alfredo; Fothergill, A. W.; Pisa, E.; Giannini, D.; Rinaldi, M. G.; Scalise, G.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/50641
Citazioni:
Posaconazole prophylaxis in experimental systemic zygomycosis / Barchiesi, F., Spreghini, E., Santinelli, A., Fothergill, A.W., Pisa, E., Giannini, D., Rinaldi, M.G., Scalise, G.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 51:(2007), pp. 73-77. [10.1128/AAC.00969-06]

Fluconazole susceptibility of Candida spp. isolates collected over nine years in a teaching hospital of Ancona, Italy.
Anno: 2007
Rivista: JOURNAL OF CHEMOTHERAPY
Autori/autrici: Barchiesi, Francesco; Arzeni, D; Greganti, G; Marigliano, A; Tomassetti, S; Spreghini, E; Scalise, G.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75405
Citazioni:
Fluconazole susceptibility of Candida spp. isolates collected over nine years in a teaching hospital of Ancona, Italy / Barchiesi, F., Arzeni, D., Greganti, G., Marigliano, A., Tomassetti, S., Spreghini, E., Scalise, G.. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - 19:(2007), pp. 58-61.
Abstract:
The in vitro activity of fluconazole was investigated against 476 yeast isolates collected during a 9-year period (1997-2005) from patients hospitalised in a teaching hospital of Ancona. They included 373 isolates of Candida albicans, 53 of Candida glabrata and 50 of Candida parapsilosis. Minimum in...hibitory concentrations (MICs) determined in accordance with the Clinical Laboratory Standards Institute methodology showed that 96% of the isolates were susceptible (MIC < or =8.0 microg/ml). The uncommon, resistant isolates (MIC > or =64 microg/ml) were randomly distributed over time. Our data show that resistance to fluconazole in this geographical area is a rare event and suggest that this triazole can still represent first-line therapy in our institution.
Continua a leggere

Voriconazole and multidrug resistance in Candida albicans.
Anno: 2007
Rivista: MYCOSES
Autori/autrici: Wakieć, R; Prasad, R; Morschhäuser, J; Barchiesi, Francesco; Borowski, E; Milewski, S.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75404
Citazioni:
Voriconazole and multidrug resistance in Candida albicans / Wakieć, R., Prasad, R., Morschhäuser, J., Barchiesi, F., Borowski, E., Milewski, S.. - In: MYCOSES. - ISSN 0933-7407. - 50:(2007), pp. 109-115. [10.1111/j.1439-0507.2006.01327.x]
Abstract:
In vitro activity of voriconazole against fluconazole-resistant Candida albicans clinical isolates with identified molecular basis of multidrug resistance (MDR) and recombinant Saccharomyces cerevisiae expressing C. albicans genes coding for major multidrug transporters, CaCdr1p, CaCdr2p or CaMdr1p,... was compared with that of fluconazole, ketoconazole and clotrimazole. It was found that overexpression of the MDR genes made the yeast cells less susceptible to voriconazole. The voriconazole resistance indexes, defined as a ratio of minimum inhibitory concentrations (MICs) determined for MDR and sensitive cells, were comparable with those determined for fluconazole. Voriconazole effectively competed with rhodamine 6G for the active efflux mediated by CaCdr1p and CaCdr2p.
Continua a leggere

Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2).
Anno: 2007
Rivista: JOURNAL OF CLINICAL MICROBIOLOGY
Autori/autrici: RODRIGUEZ TUDELA, Jl; Donnelly, Jp; Pfaller, Ma; Chryssantou, E; Warn, P; Denning, Dw; ESPINEL INGROFF, A; Barchiesi, Francesco; CUENCA ESTRELLA, M.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/30468
Citazioni:
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2) / RODRIGUEZ TUDELA, J.l., Donnelly, J.p., Pfaller, M.a., Chryssantou, E., Warn, P., Denning, D.w., ESPINEL INGROFF, A., Barchiesi, F., CUENCA ESTRELLA, M.. - In: JOURNAL OF CLINICAL MICROBIOLOGY. - ISSN 0095-1137. - 45:(2007), pp. 109-111. [10.1128/JCM.01969-06]
Abstract:
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Subcommittee on Antifungal Susceptibility Testing recently published a standard for determining the susceptibility of fermentative yeasts to antifungals. From the beginning, the EUCAST and its North American counterpart, the C...LSI, decided to work together in order to establish common standards. As part of this exercise, the susceptibility of a set of 475 yeast isolates was tested by both standards. The intraclass correlation coefficient and the equations defining the linear regression between both methods were estimated. Both methods produced very similar results, with an intraclass correlation coefficient of 0.954 (0.945 to 0.962), although linear regression analysis shows that the EUCAST standard resulted in slightly lower MICs. There were only eight isolates showing at least four twofold dilution MIC differences between both standards. After 24 h of incubation, the MICs obtained by the CLSI method were equivalent to those obtained by the EUCAST standard. In summary, both methods produce very similar MICs, indicating that methodology does not pose any obstacle to obtaining uniform standards for antifungal susceptibility testing of yeasts
Continua a leggere

Caspofungin in combination with amphotericin B against Candida parapsilosis.
Anno: 2007
Rivista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Autori/autrici: Barchiesi, Francesco; Spreghini, E; Tomassetti, S; Giannini, D; Scalise, G.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75403
Citazioni:
Caspofungin in combination with amphotericin B against Candida parapsilosis / Barchiesi, F., Spreghini, E., Tomassetti, S., Giannini, D., Scalise, G.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 51:(2007), pp. 941.-945. [10.1128/AAC.00880-06]
Abstract:
Candida parapsilosis has emerged as an important nosocomial pathogen. In the present study, a checkerboard broth microdilution method was performed to investigate the in vitro activities of caspofungin (CAS) in combination with amphotericin B (AMB) against three clinical isolates of C. parapsilosis.... Although there was a significant reduction of the MIC of one or both drugs used in combination, an indifferent interaction (fractional inhibitory concentration index greater than 0.50 and less than or equal to 4.0) was observed in 100% of cases. This finding was confirmed by killing curve studies. By a disk diffusion assay, the halo diameters produced by antifungal agents in combination were often significantly greater than those produced by each drug alone. Antagonism was never observed. In a murine model of systemic candidiasis, CAS at either 0.25 or 1 mg/kg/day combined with AMB at 1 mg/kg/day was significantly more effective than each single drug at reducing the colony counts in kidneys. Higher doses of the echinocandin (i.e., 5 and 10 mg/kg/day) combined with the polyene did not show any advantage over CAS alone. Overall, our study showed a positive interaction of CAS and AMB against C. parapsilosis.
Continua a leggere

Effects of caspofungin against Candida guilliermondii and Candida parapsilosis.
Anno: 2006
Rivista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Autori/autrici: Barchiesi, Francesco; Spreghini, E; Tomassetti, S; Della Vittoria, A; Arzeni, D; Manso, E; Scalise, G.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/30470
Citazioni:
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis / Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E., Scalise, G.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 50:(2006), pp. 2719-2727. [10.1128/AAC.00111-06]
Abstract:
The in vitro activity of caspofungin (CAS) was investigated against 28 yeast isolates belonging to Candida albicans (n = 5), Candida guilliermondii (n = 10), and Candida parapsilosis (n = 13). CAS MICs obtained by broth dilution and Etest methods clearly showed a rank order of susceptibility to the ...echinocandin compound with C. albicans > C. parapsilosis > C. guilliermondii. Similarly, time-kill assays performed on selected isolates showed that CAS was fungistatic against C. albicans and C. parapsilosis, while it did not exert any activity against C. guilliermondii. In a murine model of systemic candidiasis, CAS given at doses as low as 1 mg/kg of body weight/day was effective at reducing the kidney burden of mice infected with either C. albicans or C. guilliermondii isolates. Depending on the isolate tested, mice infected with C. parapsilosis responded to CAS given at 1 and/or 5 mg/kg/day. However, the overall CFU reduction for C. guilliermondii and C. parapsilosis was approximately 100-fold less than that for C. albicans. Our study shows that CAS was active in experimental systemic candidiasis due to C. guilliermondii and C. parapsilosis, but this activity required relatively high drug dosages.
Continua a leggere

Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital.
Anno: 2006
Rivista: CLINICAL MICROBIOLOGY AND INFECTION
Autori/autrici: Bedini, A; Venturelli, C; Mussini, C; Guaraldi, G; Codeluppi, M; Borghi, V; Rumpianesi, F; Barchiesi, Francesco; Esposito, R.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75397
Citazioni:
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital / Bedini, A., Venturelli, C., Mussini, C., Guaraldi, G., Codeluppi, M., Borghi, V., Rumpianesi, F., Barchiesi, F., Esposito, R.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - 12:(2006), pp. 75-80. [10.1111/j.1469-0691.2005.01310.x]
Abstract:
The epidemiological and antifungal susceptibility data for 94 episodes of candidaemia in an Italian tertiary-care hospital between January 2000 and August 2003 were evaluated by prospective laboratory-based surveillance. The incidence of fungaemia was 0.90 episodes/10 000 patient-days, and the most ...common species isolated were Candida albicans (40.4%), Candida parapsilosis (22.3%), Candida tropicalis (16.0%) and Candida glabrata (12.8%). Among 24 patients who received antifungal prophylaxis, non-albicans Candida spp. were more prevalent than C. albicans (p 0.012). The 30-day mortality rate was high (38.2%), particularly for haematological (71.4%) and solid-organ transplant patients (50.0%), and in individuals with C. tropicalis and C. glabrata bloodstream infections (60.0% and 50.0%, respectively). In-vitro susceptibility tests demonstrated that 95% of the isolates were susceptible to amphotericin B (MIC < 2 mg/L), 98.1% to posaconazole (MIC < 1 mg/L), 95.8% to flucytosine (MIC < 32 mg/L) and fluconazole (MIC < 64 mg/L), and 94.7% to itraconazole (MIC < 1 mg/L). Posaconazole was active (MIC 0.5 mg/L) against all three isolates of Candida krusei, which had reduced susceptibility to both fluconazole and itraconazole. Overall, non-albicans Candida spp. accounted for 60% of the episodes of candidaemia, which could be related to the use of antifungal prophylaxis. Resistance is still uncommon in Candida spp. recovered from blood cultures. The in-vitro activity of posaconazole is encouraging, and this agent could play an important role in the management of invasive candidiasis, including episodes caused by inherently less susceptible species such as C. krusei
Continua a leggere

Candida guilliermondii fungemia in patients with hematologic malignancies.
Anno: 2006
Rivista: JOURNAL OF CLINICAL MICROBIOLOGY
Autori/autrici: Girmenia, C; Pizzarelli, G; Cristini, F; Barchiesi, Francesco; Spreghini, E; Scalise, G; Martino, P.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75398
Citazioni:
Candida guilliermondii fungemia in patients with hematologic malignancies / Girmenia, C., Pizzarelli, G., Cristini, F., Barchiesi, F., Spreghini, E., Scalise, G., Martino, P.. - In: JOURNAL OF CLINICAL MICROBIOLOGY. - ISSN 0095-1137. - 44:(2006), pp. 2458-2464. [10.1128/JCM.00356-06]
Abstract:
The microbiological, clinical, and epidemiological features of most non-Candida albicans Candida species are well known, but much less is known about species such as Candida guilliermondii, an uncommon pathogen causing a variety of deep-seated infections in immunocompromised hosts. To characterize C.... guilliermondii fungemia in patients with hematological malignancies and its susceptibility to antifungal drugs, all cases of C. guilliermondii fungemia diagnosed in our department between 1983 and 2005 were retrospectively analyzed and the literature was reviewed. C. guilliermondii caused 29/243 (11.7%) candidemia episodes diagnosed during the study period. Central venous catheters were the documented sources of candidemia in 19/29 episodes (65.5%), and invasive tissue infections were documented in 2 (6.9%). In the remaining eight, the catheter was not removed and the source of the fungemia remained obscure. Seven episodes ended in death, but only one could be attributed to invasive C. guilliermondii infection. Molecular typing data reveal no evidence of common infection sources. Isolates displayed high rates of in vitro susceptibility to amphotericin B (100%), voriconazole (95%), and fluconazole (90%) and lower rates of in vitro susceptibility to flucytosine (86%), itraconazole (76%), and caspofungin (33%). Our literature review confirms that C. guilliermondii is a significantly more frequent cause of candidemia among cancer patients compared with the general hospital population. It accounted for <1% of the total number of Candida bloodstream isolates reported in the articles we reviewed, with higher rates in Europe (1.4%) and Asia (1.8%) compared with North America (0.3%).
Continua a leggere

Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report.
Anno: 2006
Rivista: JOURNAL OF CHEMOTHERAPY
Autori/autrici: Pasticci, Mb; Barchiesi, Francesco; Fallani, S; Palladino, N; Lapalorcia, Lm; Gubbiotti, M; Cozzari, M; Novelli, A; Baldelli, F.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75402
Citazioni:
Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report / Pasticci, M.b., Barchiesi, F., Fallani, S., Palladino, N., Lapalorcia, L.m., Gubbiotti, M., Cozzari, M., Novelli, A., Baldelli, F.. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - 18:(2006), pp. 549-553.
Abstract:
Organ transplant recipients are at increased risk for severe invasive aspergillosis, and amphotericin deoxycholate has been the standard treatment for many years. Currently, however, lipid formulations are preferred due to their few side effects. Also, a number of new antifungal drugs have been deve...loped including new azoles and echinocandins. Caspofungin is the first of the echinocandin derivatives patented to treat patients with invasive aspergillosis who are refractory or intolerant to other therapies. A renal transplant patient on immunosuppressive treatment with chronic hepatitis B virus infection was admitted with fever, hemophthisis and lung consolidation, diagnosed to be probably caused by Aspergillus flavus. The patient developed cholestatic hepatitis most likely related to itraconazole. Clinical failure and in vitro itraconazole resistance of the isolate was also documented while the patient was receiving itraconazole at a reduced dosage. Caspofungin was administered once a day as ambulatory treatment and was well tolerated. Clinical improvement was observed after 6 weeks of treatment and no hepatic toxicity was documented. Caspofungin seems to be a potentially useful antifungal agent in renal transplant patients with invasive aspergillosis. Further evaluation of the efficacy of caspofungin is needed.
Continua a leggere

LA SIEROLOGIA TIPO-SPECIFICA PER HERPES SYMPLEX TIPO 2 NELLA GESTIONE DEI PAZIENTI HIV POSITIVI
Anno: 2005
Rivista: MICROBIOLOGIA MEDICA
Autori/autrici: Pauri, P.; Balercia, M.; Barchiesi, Francesco; Butini, L.; Costantini, Andrea; Del Gobbo, R.; Marinelli, K.; Tomassini, T.
Lingua: ITA
Classificazione IRIS: 1.5 Abstract in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/245827
Citazioni:
LA SIEROLOGIA TIPO-SPECIFICA PER HERPES SYMPLEX TIPO 2 NELLA GESTIONE DEI PAZIENTI HIV POSITIVI / Pauri, P., Balercia, M., Barchiesi, F., Butini, L., Costantini, A., Del Gobbo, R., Marinelli, K., Tomassini, T.. - In: MICROBIOLOGIA MEDICA. - ISSN 2280-6423. - STAMPA. - 20:(2005), pp. 199-199. [10.4081/mm.2005.3598]
Abstract:
Vedi allegato.

Efficacy of caspofungin against Aspergillus terreus
Anno: 2005
Rivista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Autori/autrici: Barchiesi, Francesco; Spreghini, E.; Santinelli, Alfredo; Fothergill, A. W.; Fallani, S.; Manso, E.; Pisa, E.; Giannini, D.; Novelli, A.; Cassetta, M. I.; Mazzei, T.; Rinaldi, M. G.; Scalise, G.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/51031
Citazioni:
Efficacy of caspofungin against Aspergillus terreus / Barchiesi, F., Spreghini, E., Santinelli, A., Fothergill, A.W., Fallani, S., Manso, E., Pisa, E., Giannini, D., Novelli, A., Cassetta, M.I., Mazzei, T., Rinaldi, M.G., Scalise, G.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 49:(2005), pp. 5133-5135. [10.1128/AAC.49.12.5133-5135.2005]

Genotypic variation and antifungal susceptibilities of Candida pelliculosa clinical isolates.
Anno: 2005
Rivista: JOURNAL OF MEDICAL MICROBIOLOGY
Autori/autrici: Barchiesi, Francesco; Tortorano, Am; Di Francesco, Lf; Rigoni, A; Giacometti, Andrea; Spreghini, E; Scalise, Giorgio; Viviani, Ma
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/73960
Citazioni:
Genotypic variation and antifungal susceptibilities of Candida pelliculosa clinical isolates / Barchiesi, F., Tortorano, A.m., Di Francesco, L.f., Rigoni, A., Giacometti, A., Spreghini, E., Scalise, G., Viviani, M.a.. - In: JOURNAL OF MEDICAL MICROBIOLOGY. - ISSN 0022-2615. - STAMPA. - 54:(2005), pp. 279-285.
Abstract:
At the Istituto Ricovero Cura Carattere Scientifico, Ospedale Maggiore di Milano, Italy, Candida pelliculosa accounted for 3.3 and 4.4 % of all Candida species other than Candida albicans collected during 1996 and 1998, respectively. Genetic variability was investigated by electrophoretic karyotypin...g and inter-repeat PCR, and the susceptibility to five antifungal agents of 46 strains isolated from 37 patients during these 2 years was determined. Combination of the two typing methods yielded 14 different DNA types. Although the majority of DNA types were randomly distributed among different units, one DNA type was significantly more common in patients hospitalized in a given unit compared with those from other wards (P=0.034), whereas another DNA type was more frequently isolated in patients hospitalized during 1996 than in those hospitalized during 1998 (P=0.002). Fluconazole, itraconazole and posaconazole MIC90 values were 16, 1 and 4 microg ml-1, respectively. All isolates but three were susceptible in vitro to flucytosine. All isolates were susceptible in vitro to amphotericin B. These data suggest that there are possible relationships among strains of C. pelliculosa, wards and time of isolation. Amphotericin B seems to be the optimal drug therapy in infections due to this yeast species.
Continua a leggere

Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
Anno: 2005
Rivista: JOURNAL OF CLINICAL MICROBIOLOGY
Autori/autrici: ESPINEL INGROFF, A; Barchiesi, Francesco; CUENCA ESTRELLA, M; Fothergill, A; Pfaller, Ma; Rinaldi, M; RODRIGUEZ TUDELA, Jl; Verweij, P. E.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/31323
Citazioni:
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study / ESPINEL INGROFF, A., Barchiesi, F., CUENCA ESTRELLA, M., Fothergill, A., Pfaller, M.a., Rinaldi, M., RODRIGUEZ TUDELA, J.l., Verweij, P.E.. - In: JOURNAL OF CLINICAL MICROBIOLOGY. - ISSN 0095-1137. - 43:(2005), pp. 4535-4540. [10.1128/JCM.43.9.4535-4540.2005]

Caspofungin in combination with amphotericin B against Candida glabrata.
Anno: 2005
Rivista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Autori/autrici: Barchiesi, Francesco; Spreghini, E; Fothergill, Aw; Arzeni, D; Greganti, G; Giannini, D; Rinaldi, Mg; Scalise, G.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75391
Citazioni:
Caspofungin in combination with amphotericin B against Candida glabrata / Barchiesi, F., Spreghini, E., Fothergill, A.w., Arzeni, D., Greganti, G., Giannini, D., Rinaldi, M.g., Scalise, G.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 49:(2005), pp. 2546-2549. [10.1128/AAC.49.6.2546-2549.2005]

Comparative analysis of pathogenicity of Cryptococcus neoformans serotypes A, D and AD in murine cryptococcosis.
Anno: 2005
Rivista: JOURNAL OF INFECTION
Autori/autrici: Barchiesi, Francesco; Cogliati, M; Esposto, Mc; Spreghini, E; Schimizzi, Am; Wickes, Bl; Scalise, G; Viviani, Ma
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75392
Citazioni:
Comparative analysis of pathogenicity of Cryptococcus neoformans serotypes A, D and AD in murine cryptococcosis / Barchiesi, F., Cogliati, M., Esposto, M.c., Spreghini, E., Schimizzi, A.m., Wickes, B.l., Scalise, G., Viviani, M.a.. - In: JOURNAL OF INFECTION. - ISSN 0163-4453. - 51:(2005), pp. 10-16. [10.1016/j.jinf.2004.07.013]

International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
Anno: 2005
Rivista: JOURNAL OF CLINICAL MICROBIOLOGY
Autori/autrici: Espinel Ingroff, A; Barchiesi, Francesco; Cuenca Estrella, M; Pfaller, Ma; Rinaldi, M; Rodriguez Tudela, Jl; Verweij, Pe
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75393
Citazioni:
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole / Espinel Ingroff, A., Barchiesi, F., Cuenca Estrella, M., Pfaller, M.a., Rinaldi, M., Rodriguez Tudela, J.l., Verweij, P.e.. - In: JOURNAL OF CLINICAL MICROBIOLOGY. - ISSN 0095-1137. - 43:(2005), pp. 3884-3889. [10.1128/JCM.43.8.3884-3889.2005]
Abstract:
The aim of this study was to compare MICs of fluconazole, itraconazole, posaconazole, and voriconazole obtained by the European Committee on Antibiotic Susceptibility Testing (EUCAST) and CLSI (formerly NCCLS) methods in each of six centers for 15 Candida albicans (5 fluconazole-resistant and 4 su...sceptibledose- dependent [S-DD] isolates), 10 C. dubliniensis, 7 C. glabrata (2 fluconazole-resistant isolates), 5 C. guilliermondii (2 fluconazole-resistant isolates), 10 C. krusei, 9 C. lusitaniae, 10 C. parapsilosis, and 5 C. tropicalis (1 fluconazole-resistant isolate) isolates. CLSI MICs were obtained visually at 24 and 48 h and spectrophotometric EUCAST MICs at 24 h. The agreement (within a 3-dilution range) between the methods was species, drug, and incubation time dependent and due to lower EUCAST than CLSI MICs: overall, 94 to 95% with fluconazole and voriconazole and 90 to 91% with posaconazole and itraconazole when EUCAST MICs were compared against 24-h CLSI results. The agreement was lower (85 to 94%) against 48-h CLSI endpoints. The overall interlaboratory reproducibility by each method was >92%. When the comparison was based on CLSI breakpoint categorization, the agreement was 68 to 76% for three of the four species that included fluconazoleresistant and S-DD isolates; 9% very major discrepancies (<8 mcg/ml versus >64 mcg/ml) were observed among fluconazole-resistant isolates and 50% with voriconazole (<1 mcg/ml versus >4 mcg/ml). Similar results were observed with itraconazole for seven of the eight species evaluated (28 to 77% categorical agreement). Posaconazole EUCAST MICs were also substantially lower than CLSI MIC modes (0.008 to 1 mcg/ml versus 1 to >8 mcg/ml) for some of these isolates. Therefore, the CLSI breakpoints should not be used to interpret EUCAST MIC data.
Continua a leggere

Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata.
Anno: 2005
Rivista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Autori/autrici: Barchiesi, Francesco; Spreghini, E; Tomassetti, S; Arzeni, D; Giannini, D; Scalise, G.
Lingua: ENG
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/75395
Citazioni:
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata / Barchiesi, F., Spreghini, E., Tomassetti, S., Arzeni, D., Giannini, D., Scalise, G.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 49:(2005), pp. 4989-4992. [10.1128/AAC.49.12.4989-4992.2005]
Abstract:
We investigated the fungicidal activity of caspofungin (CAS) and amphotericin B (AMB) against 16 clinical isolates of Candida glabrata. The minimum fungicidal concentrations (MFCs) of CAS were similar to those of AMB, ranging from 2.0 to >8.0 mcg/ml. Time-kill assays performed on selected isola...tes showed that AMB was fungicidal at concentrations four times the MIC while CAS was not. A neutropenic-mouse model of disseminated infection was utilized to determine the residual fungal kidney burden. While doses as low as 0.3 and 1 mg/kg of body weight/day of CAS and AMB, respectively, were effective at reducing the counts with respect to controls, organ sterilization was reached when both drugs were administered at 5 mg/kg/day. Our study reveals that, similar to AMB, CAS has the potential for a fungicidal effect in vivo against this difficult-to-treat fungal pathogen.
Continua a leggere

In vitro activities of voriconazole in combination with other three antifungal agents against Candida glabrata
Anno: 2004
Rivista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Autori/autrici: Barchiesi, Francesco; Spreghini, E.; Maracci, M.; Fothergill, A. W.; Baldassarri, I.; Rinaldi, M. G.; Scalise, G.
Classificazione IRIS: 1.1 Articolo in rivista
Scheda completa IRIS: https://iris.univpm.it/handle/11566/31315
Citazioni:
In vitro activities of voriconazole in combination with other three antifungal agents against Candida glabrata / Barchiesi, F., Spreghini, E., Maracci, M., Fothergill, A.W., Baldassarri, I., Rinaldi, M.G., Scalise, G.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 48:(2004), pp. 3317-3322.